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Abstract
Response-adaptive designs allow the randomization probabilities to change during the course of
a trial based on cumulated response data, so that a greater proportion of patients can be allocated
to the better performing treatments. A major concern over the use of response-adaptive designs in
practice, particularly from a regulatory viewpoint, is controlling the type I error rate. In particular,
we show that the na¨ıve z-test can have an inflated type I error rate even after applying a Bonfer-
roni correction. Simulation studies have often been used to demonstrate error control, but do not
provide a guarantee. In this paper, we present adaptive testing procedures for normally distributed
outcomes that ensure strong familywise error control, by iteratively applying the conditional invari-
ance principle. Our approach can be used for fully sequential and block randomized trials, and for
a large class of adaptive randomization rules found in the literature. We show there is a high price
to pay in terms of power to guarantee familywise error control for randomization schemes with
extreme allocation probabilities. However, for proposed Bayesian adaptive randomization schemes
in the literature, our adaptive tests maintain or increase the power of the trial compared to the
z-test. We illustrate our method using a three-armed trial in primary hypercholesterolemia.
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1 Introduction
Clinical trials typically randomize patients using a fixed randomization scheme, where the probabilities
of assigning patients to the experimental treatments and control are pre-specified and constant. A
common method is to simply use equal randomization to the different arms of the trial. However, such
randomization schemes can mean that a substantial proportion of the trial participants will continue
to be allocated to treatments that are not the best available, even if interim data indicates that
one treatment is likely to be superior. Response-adaptive trials address this concern by adaptively
changing the randomization probabilities, so that a greater proportion of patients are allocated to
the treatment arm which has a better performance based on the cumulated response data. Hence, as
the trial continues and accumulates more data, patients in the trial can benefit from having a higher
probability of being assigned to a better treatment.
Many classes of response-adaptive randomization schemes have been proposed in the literature for
binary outcomes. Randomization schemes based on urn models (such as the randomized play-the-
winner rule (Wei and Durham, 1978)), and adaptive biased coin designs (such as the doubly-adaptive
biased coin design (Eisele, 1994)), have been extensively studied, with a comprehensive presentation
given by Hu and Rosenberger (2006). Many Bayesian adaptive randomization (BAR) schemes have
also been proposed (Thall and Wathen, 2007; Trippa et al., 2012; Yin et al., 2012; Wason and Trippa,
2014), where the randomization probabilities are recursively updated using a Bayesian model for the
patient outcomes.
There is also a growing interest in response-adaptive randomization for continuous responses. For
example, there are schemes based on doubly-adaptive biased coin designs (Hu and Rosenberger, 2006;
Zhang and Rosenberger, 2006; Biswas et al., 2007), urn-based drop-the-loser designs (Ivanova et al.,
2006) and bandit-based designs (Smith and Villar, 2017). A comprehensive recent overview is given
by Biswas and Bhattacharya (2016). In this paper, our focus is on normally distributed outcomes,
which are encountered in many clinical trials. Indeed, 23 out of the 59 multi-arm clinical trials
identified in a review by Wason et al. (2014) had a continuous outcome.
A comprehensive discussion of the relative advantages and disadvantages of adaptive versus fixed
randomization is beyond the scope of this paper. Indeed, the use of adaptive randomization is a
widely discussed and somewhat controversial topic in clinical trials. For binary responses, a number
of comparisons (Korn and Freidlin, 2011; Berry, 2011; Thall et al., 2015; Wathen and Thall, 2017)
have focused on the BAR scheme proposed by Thall and Wathen (2007). Particularly in the two-arm
setting, fixed randomisation appears to be preferable to this scheme in terms of power and the number
of treatment failures, except when the number of patients to be treated beyond the trial is small (as
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in rare diseases) or where there are large treatment differences (Lee et al., 2012; Du et al., 2015).
However, even in the two-arm setting, optimal response-adaptive schemes (i.e. those that target
some formal optimality criteria) have been shown to have benefits over fixed randomisation by increas-
ing both power and patient benefit simultaneously (Rosenberger et al., 2001; Rosenberger and Hu,
2004; Tymofyeyev et al., 2007; Bello and Sabo, 2016). In the multi-arm setting, which is the focus of
this paper, adaptive randomisation can have further advantages over fixed randomization (Berry, 2011;
Wason and Trippa, 2014; Hey and Kimmelman, 2015; Berry, 2015), particularly for more complex trial
designs.
Response-adaptive designs also have application outside of the context of clinical trials. For ex-
ample, multi-arm bandit models are used for market learning in economics (Bergemann and Vlimki,
2006) and to improve modern production systems that emphasize ‘continuous improvement’ (Scott,
2010). Some of the ethical concerns surrounding adaptive randomization (Hey and Kimmelman, 2015)
would not apply in these contexts.
Despite the extensive literature on response-adaptive randomization, relatively few clinical trials
have actually used such schemes in practice. One of the first examples, which used a randomized
play-the-winner rule, was a trial of extracorporeal membrane oxygenation to treat newborns with
respiratory failure (Bartlett et al., 1985). More recent examples include a three-armed trial in untreated
patients with adverse karyotype acute myeloid leukemia (Giles et al., 2003), which used BAR. The
ongoing I-SPY 2 trial (Park et al., 2016; Rugo et al., 2016), which screens drugs in neoadjuvant breast
cancer, also uses BAR as part of its design.
A key concern over using response-adaptive randomization, particularly from a regulatory perspec-
tive, is ensuring that the type I error rate is controlled. Indeed, draft regulatory guidance from the
U.S. Food and Drug Administration (2010) includes adaptive randomization under a section entitled
“Adaptive Study Designs Whose Properties Are Less Well Understood”. It then goes on to state that
“particular attention should be paid to avoiding bias and controlling the Type I error rate” (Food and
Drug Administration, 2010, pg. 27) when using adaptive randomization in trials.
In a multi-arm trial, multiple hypotheses are tested simultaneously by design, which leads to a
multiple testing problem. To account for this, testing procedures are used that guarantee strong control
of the familywise error rate (FWER), which ensures the maximum probability of making at least one
type I error is controlled. For confirmatory trials in particular, demonstrating strong control of the
FWER is often required by regulators (Food and Drug Administration, 2010; European Medicines
Agency, 2002).
For response-adaptive trials, a rigorous proof of FWER control for a particular design is difficult
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given the complexities of the treatment allocation process. Hence error control has typically either been
demonstrated through simulation studies, or by exploiting the asymptotic structure of the adaptive
randomization procedure (Hu and Rosenberger, 2006; Zhu and Hu, 2010). However, neither method
provides a guarantee of FWER control, particularly with small sample sizes. Gutjahr et al. (2011)
showed how to achieve strong control of the FWER for normally distributed outcomes in a two-stage
design incorporating response-adaptive randomization. However, our focus is on general response-
adaptive trials, without the necessity of restricting to two stages or having a final stage of equal
randomization.
In this paper, we show how to guarantee strong control of the FWER for both fully sequential
and block randomized response-adaptive trials, for a large class of adaptive randomization rules. Our
proposed procedure works by reweighting the usual z-statistic through an iterative application of the
conditional invariance principle. The resulting adaptive test statistic can then be used to test the
elementary null hypothesis that a treatment is superior to the control.
The rest of the paper is organised as follows. In Section 2, we describe the proposed method
for fully sequential response-adaptive trials with a fixed allocation to the control. This method is
then modified for block randomized response-adaptive trials in Section 3, for both a fixed or adaptive
control allocation. Simulation studies for the proposed methods are presented in Section 4, and
Section 5 gives a case study based on a trial in primary hypercholesterolemia. We conclude with a
discussion in Section 6. All proof details can be found in the Appendices.
2 Fully sequential response-adaptive trials
2.1 Trial setting
Suppose a trial is conducted to test h > 1 experimental treatments against a common control, using the
following design. A total of n patients are allocated to the experimental treatments, and n0 patients
are allocated to the control, where n0 and n are fixed in advance. Patients are allocated to the
different experimental treatments using response-adaptive randomization, where we assume that the
randomization rule does not depend on the control information. We also assume the allocation to
the control is fixed; that is, the probability of assigning a patient to the control is pre-specified and
constant. Maintaining allocation to the control is recommended by the Food and Drug Administration
(2010), since it best maintains the power of the trial, and helps address the concern about changing
patient characteristics over the course of the trial.
The response-adaptive randomization for the experimental treatments starts with a burn-in pe-
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riod B, which uses equal randomization to allocate ri > 0 patients to the ith treatment (i = 1, . . . , h),
with the ri again fixed in advance. Hence a total of r =
∑h
i=1 ri patients are allocated to the ex-
perimental treatments during the burn-in period. Let ak denote the treatment allocation for the kth
experimental patient (k = 1, . . . , n), where ak = i if the kth patient is allocated to the ith treatment.
Also, let Xk denote the efficacy outcome for the kth patient. Similarly, let X0j denote the efficacy
outcomes for the jth patient on the control (j = 1, . . . , n0). We assume that
X0j ∼ N(µ, σ2), Xk |ak=i ∼ N(µ+ δi, σ2)
The variance σ2 is assumed known and, without loss of generality, we set σ2 = 1. Here δi represents the
incremental benefit of treatment i compared to the control, and is the parameter of interest. Finally,
let ni denote the total number of allocations to the ith experimental treatment, including the burn-in
period.
2.2 Hypothesis testing
The elementary null hypotheses of interest are Hi : δi = 0 against the one-sided alternatives H¯i : δi > 0.
We discuss the case when Hi : δi ≤ 0 at the end of Section 2.5. One general method to control for
multiple testing is to use the closure principle (Marcus et al., 1976) and consider all intersection
hypotheses HI , where I ⊆ {1, . . . , h}. To strongly control the FWER, we reject an elementary null
hypothesis Hi if we also reject every HI with i ∈ I using a local level-α test. Hence we need to define
a valid level-α test for all the intersection hypotheses HI . The na¨ıve z-test for HI , which does not
take into account the response-adaptive randomization used in the trial, rejects HI if the test statistic
TI =
n∑
k=1
(
1{ak∈I}
Xk
nI
)
−
n0∑
j=1
X0j
n0
is greater than zα (1/nI + 1/n0)
1/2, where nI =
∑
i∈I ni and zα is the (1−α) standard normal quantile.
As an alternative to using the closure principle with the test statistic above, we could control the
FWER by simply using a Bonferroni correction, or a step-up/step-down procedure such as the Holm
procedure. These would only involve calculating test statistics for the h elementary null hypotheses,
i.e. calculating TI for I = {i} (i = 1, . . . , h). Hence we present the methodology assuming the closure
principle will be used, with the Bonferroni and Holm procedures considered as special cases. We return
to this issue in Section 4.
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2.3 Inflation of the familywise error rate
Since the z-test ignores the adaptive randomization used, it is possible to inflate the FWER. As an
example, consider the following adaptive randomization scheme for h = 2 treatments:
ak+1 =

2 if
∑k
j=1(1{aj=1}
Xj
n1k
) > 0.5
1 otherwise
where n1k =
∑k
j=1 1{aj=1}. This can be viewed as implementing early stopping for efficacy for treat-
ment 1, which is not taken into account using the na¨ıve z-test.
We ran a simulation study to calculate the type I error rate using the above randomization scheme.
We set α = 0.05, n0 = n = 60, r1 = r2 = 5 and the true treatment means µ = 0, δ1 = 0, δ2 = 1. The
type I error rate as averaged over 105 simulations is 10.4%, more than double the nominal 5% level.
We subsequently refer to allocation rules of this type as ‘type I error inflator’ rules (which clearly
would never be used in practice).
2.4 Auxiliary design
Working with the actual design of the trial is difficult because the response-adaptive randomization
affects the distribution of the usual z-test statistics. Hence for each HI we introduce a simpler design,
called the auxiliary design, for which we do know the distribution. The actual trial design can then be
viewed as a series of data-dependent modifications of the auxiliary design, where we account for the
modifications using the conditional invariance principle. The auxiliary designs are purely hypothetical,
and are only used to construct the modified tests for the actual design. As well, the allocations in the
auxiliary designs are fixed before the start of the actual trial.
The auxiliary design for hypothesis HI is as follows. As in the actual design, a total of n patients are
allocated to the experimental treatments, and n0 patients are allocated to the control. The allocations
and responses to the control treatment are the same as the actual design. For the patients allocated to
the experimental treatments, the auxiliary design starts with a burn-in period B with r patients that
is identical to the actual design. The subsequent n − r − 1 allocations are given by a fixed sequence
(br+1, . . . , bn−1), which can be chosen arbitrarily. These allocations can be considered as a ‘guess’ of
a likely allocation sequence of the actual trial design. One possibility would be to randomize equal
numbers of patients for each treatment. The final allocation bn must be to one of the treatments in I.
We now introduce some notation for the auxiliary design. Let n′i =
∑n
j=1 1{bj=i} denote the total
number of allocations to the ith experimental treatment. Also let mi,k =
∑n
j=k 1{bj=i} denote the
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total number of allocations to the ith treatment for patients (k, k+ 1, . . . , n). We define n′I =
∑
i∈I n
′
i
and mI,k =
∑
i∈I mi,k. Under the auxiliary design, n
′
i is fixed for all i, and hence under HI , the usual
z-statistic
T ′I =
n∑
k=1
(
1{bk∈I}
Yk
n′I
)
−
n0∑
j=1
X0j
n0
is normally distributed with mean zero and variance (1/n′I +1/n0). Hence we reject HI if T
′
I is greater
than zα (1/n
′
I + 1/n0)
1/2.
2.5 Adaptive test statistic
Adaptive designs, such as the trial being considered, follow a common conditional invariance principle
in order to control the type I error rate (Brannath et al., 2007). For our response-adaptive trial in
question, we apply the conditional invariance principle sequentially, where each step considers the next
patient recruited into the trial. Below we give the test statistic for testing hypothesis HI under the
actual design, given that the allocation is fully sequential. The proof of Theorem 2.1 can be found in
Appendix A.
Theorem 2.1. Under HI , the following test statistic is normally distributed with mean 0 and variance
(1/n′I + 1/n0):
T˜I =
n∑
k=1
(
1{ak∈I}
Xk
w
(I)
k
)
−
n0∑
j=1
X0j
w
(0)
n,j
where
w
(I)
k = n
′
I , w
(0)
k = n0 (k = 1, . . . , r)
w
(I)
r+l = f(λr+l, ηr+l, m˜I,r+l), w
(0)
r+l = g(λr+l, w
(I)
r+l, m˜I,r+l) (l = 1, . . . , n− r)
w
(0)
n,j = F1(w
(0)
n−1,m0,1,m0,2) (j = 1, . . . ,m0,1)
w
(0)
n,j = F2(w
(0)
n−1,m0,1,m0,2) (j = m0,1 + 1, . . . , n0)
λr+l =
mI,r+l
w
(I)
r+l−1
− n0
w
(0)
r+l−1
, ηr+l =
mI,r+l[
w
(I)
r+l−1
]2 + n0[
w
(0)
r+l−1
]2 (l = 1, . . . , n− r)
m˜I,r+l = mI,r+l + 1{ar+l∈I,br+l /∈I} − 1{ar+l /∈I,br+l∈I} (l = 1, . . . , n− r)
f(λ, η,m) =
λm− {mn0(n0η − λ2)}1/2
λ− n0η , g(λ,w,m) =
n0w
m− λw
F1(w,m1,m2) = 1{an∈I}w − 1{an /∈I}
2m1λn + [m1m2{ηn(m1 +m2)− λ2n}]1/2
λ2n −m2ηn
F2(w,m1,m2) = 1{an∈I}w − 1{an /∈I}
m2F1(w,m1,m2)
m1 + λnF1(w,m1,m2)
m0,1 +m0,2 = n0, m0,1 > 0, m0,2 > 0
Hence we reject HI if T˜I is greater than zα (1/n
′
I + 1/n0)
1/2. In Appendix B, we give some simple
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numerical examples of how the weights change over the course of a trial. In practice, to keep the
weights as close to the natural weight n0 for as many of the control observations as possible, we
recommend setting m0,1 = n0 − 1 and m0,2 = 1, as used for the simulation studies in Section 4.1.
In all of the scenarios that we have investigated, the weights w
(I)
k for the experimental treatments
have been positive. Hence in these cases, the test procedure also controls the FWER for the composite
null hypotheses Hi : δi ≤ 0. To see this, suppose the elementary null hypotheses are H∗i : δi = δ∗i < 0.
Under H∗I , we can rewrite the distribution of the responses X
∗
k as Xk+δ
∗
i , where Xk ∼ N(0, 1). Hence
under H∗I
pr(T˜ ∗I > c) = pr
(
T˜I > c−
n∑
k=1
1{ak∈I}
δ∗k
w
(I)
k
)
< pr(T˜I > c)
where T˜ ∗I and T˜I are the adaptive test statistics for H
∗
I and HI respectively.
3 Block randomized response-adaptive trials
3.1 Trial setting
It may not be feasible or desirable to randomize patients one-by-one in a fully sequential manner.
Instead one can use block randomization, where after the burn-in period B, patients are adaptively
randomized to the experimental treatments in blocks of size (d1, . . . , dJ) over J stages, with
∑J
j=1 dj =
n. The randomization of the jth block depends on the data up to block (j−1), as well as any external
information available at the time. Defining d0 = 0, let Dl =
∑l
j=0(r + dj) for l = 0, . . . , J , which
represents the total number of allocations by the end of lth block, with the zeroth block corresponding
to the burn-in period. For notational convenience, we let D−1 = 0. The allocation to the control is
again assumed to be fixed throughout the trial.
Due to the block structure of the trial, we can relax the assumption that the randomization rule
used for the experimental treatments does not depend on the control information. This is achieved
by splitting up the n0 patients allocated to the control into blocks. More explicitly, suppose that
during the burn-in period, r0 > 0 patients are allocated to the control, where r0 is fixed in advance.
Subsequently, in the jth block, d0j patients are allocated to the control, where
∑J
j=1(r0 + d0j) = n0.
We assume that for the final block d0J > 1.
The response-adaptive randomization at block l may now depend on the control information avail-
able at the end of block (l−1); that is, the outcome data available from the first∑l−1j=1(r0+d0j) patients
allocated to the control. For notational convenience, define d00 = 0 and let D0,l =
∑l
j=0(r0 + d0j)
(l = 0, . . . , J), which represents the total number of allocations to the control by the end of lth block.
For notational convenience, let D0,−1 = 0.
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To control the FWER, we can modify the approach described in Section 2 to account for the block
structure. As before, we have an auxiliary design for the patients on the experimental treatments, but
now in step l of the process (l ∈ {1, . . . , J}) the actual design is a data-dependent modification of all
the allocations for the patients in block l. Hence the weights for the observations in each block will
be the same, and are updated block-by-block.
3.2 Auxiliary design and adaptive test statistic
The auxiliary design for an intersection hypothesis HI is the same as described in Section 2.4, except
that we now impose a block structure on the auxiliary assignments to the experimental treatments.
As before, the auxiliary and actual designs are identical during the burn-in period B, and we require
bn ∈ I. For the auxiliary design, let n′i denote the total number of allocations to the ith treatment
(i = 1, . . . , h), including the burn-in period. Also let
m0,j =
J∑
k=j
d0k, mi,j =
n∑
k=Dj+1
1{bk=i}
denote the total number of allocations to the control and ith treatment respectively for patients in
blocks (j, j + 1, . . . , J). We define n′I =
∑
i∈I n
′
i and mI,j =
∑
i∈I mi,j .
We apply the conditional invariance principle block-by-block, where each step considers an addi-
tional block of patients recruited into the trial. This gives the following test statistic for testing HI ,
with a proof and the formulae for the weights given in Appendix C.
Theorem 3.1. If mI,J > 0 then under HI , the following test statistic is normally distributed with
mean 0 and variance (1/n′I + 1/n0) :
T˜I =
J∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
−
J∑
j=0
D0,j∑
k=D0,j−1+1
X0k
w
(0)
j
Corollary 3.2. If mI,J = 0, then let n0,J,1 + n0,J,2 = m0,J , where n0,J,1, n0,J,2 > 0. Under HI , the
following test statistic is normally distributed with mean 0 and variance (1/n′I + 1/n0):
T˜I =
J−1∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
−
J−1∑
j=0
D0,j∑
k=D0,j−1+1
X0k
w
(0)
j
−
D0,J,1∑
k=D0,J−1+1
X0k
w
(0)
J,1
−
n0∑
k=D0,J,1+1
X0k
w
(0)
J,2
We reject HI if T˜I is greater than zα (1/n
′
I + 1/n0)
1/2. In order to keep the weights as close to
the natural weight n0 for as many of the control observations as possible, we recommend setting
n0,J,1 = m0,J − 1 and n0,J,2 = 1, as used for the simulation studies in Section 4.2. In all of the
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scenarios that we have investigated, the weights w
(I)
j for the experimental treatments have all been
positive. Hence in these cases, the test procedure also controls the FWER for the composite null
hypotheses Hi : δi ≤ 0.
3.3 Extension for adaptive control allocations
Thus far, we have assumed that the allocations to the control follow some fixed scheme. We now relax
this assumption in the block-randomized setting. Since the form of the adaptive test statistic T˜I is
similar to the one presented above, the formula for T˜I can be found in Appendix D. Note that it is
possible the procedure will fail to give a valid test statistic in this setting, as shown in Appendix E.1.
4 Simulation studies
As we have already seen in Section 2.3, using the closure principle with the usual z-test does not
strongly control the FWER. An alternative method of control is to use the Bonferroni correction on
the elementary null hypotheses H1, . . . ,Hh. We also consider the Holm procedure, which is a step-
down procedure that is uniformly more powerful than Bonferroni (Holm, 1979). An advantage of both
these procedures is that only h test statistics are calculated, rather than (2h − 1) test statistics when
using the closure principle. This motivates also applying the Holm procedure to the p-values derived
from the adaptive test statistics T˜i for i = 1, . . . , h. More precisely, we use the adjusted p-values
p˜i = 1−Φ((1/n′i+1/n′0)−1/2 T˜i), instead of the usual p-values pi = 1−Φ((1/ni+1/n0)−1/2 Ti) derived
from the z-test.
To distinguish between the different methods, we call our proposed procedure that uses the closure
principle the ‘adaptive closed test’. Similarly, applying the closure principle to the usual z-test gives the
‘closed z-test’. Applying the Holm procedure to our adjusted p-values gives the ‘Holm adaptive test’,
while applying the Holm procedure to the usual p-values gives the ‘Holm z-test’. In our simulation
studies, we compare the different methods primarily by looking at the FWER. However, clearly another
key consideration is the power of the different tests. To keep the comparisons simple, and as a similar
measure to the FWER, we present results for the disjunctive power, which is the probability of rejecting
at least one false null hypothesis.
4.1 Fully sequential randomization
We first consider a fully sequential response-adaptive trial, as presented in Section 2, with m = 50
patients allocated to the experimental treatments after the burn-in and n0 = 60/h patients allocated
to the control. In the burn-in period, five patients are allocated to each of the experimental treatments.
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We set α = 0.05 and the true control mean µ = 0 for simplicity. We compare the methods under two
randomization schemes described below.
Type I error inflator : For h = 2 treatments, this is the same randomization scheme as presented in
Section 2.3. For h = 3 treatments, if
∑k
j=1(1{aj=1}Xj/n1k) > 0.5, then we randomize patient (k + 1)
to treatments 2 and 3 with equal probability.
BAR: The efficacy outcome for the ith experimental treatment follows a N(µi, 1) distribution.
For simplicity, we assign independent normal priors to the µi, so that µi ∼ N(µi,0, σ2i,0), and let
ni,K =
∑K
k=1 1{ak=i}. After observing the efficacy outcomes x = (x1, . . . , xK) for the first K patients,
the posterior for µi is as follows:
µi |X = x ∼ N
(
σ2i,0
1 + ni,Kσ2i,0
K∑
k=1
1{ak=i}xk +
ni,K
1 + ni,Kσ2i,0
µi,0 ,
σ2i,0
1 + ni,Kσ2i,0
)
We use a suggested BAR scheme of Yin et al. (2012). For h = 2 experimental treatments, the
randomization probabilities (pi1, 1− pi1) after observing the Kth patient are:
pi1 =
P (µ1 > µ2 |X = x)τ
P (µ1 > µ2 |X = x)τ + {1− P (µ1 > µ2 |X = x)}τ
For h > 2 experimental treatments, we first obtain the average of the posterior means µ¯ =
1
h
∑h
i=1 µi. The randomization probabilities pii after observing the Kth patient are:
pii =
P (µi > µ¯ |X = x)τ∑h
j=1 P (µj > µ¯ |X = x)τ
In our simulations, for simplicity we set the priors µi,0 = 0 and σ
2
i,0 = 1, while τ = 0.5.
Simulation results: Table 1 gives the results for the type I error inflator randomization scheme,
while Table 2 gives the results for BAR. The auxiliary designs in all scenarios were simply (m −
1) random draws from a discrete uniform distribution on {1, . . . , h}.
Looking first at the results for the type I error inflator in Table 1, the closed z-test does not control
the FWER in any of the scenarios where at least one null hypothesis is false, with an error rate as
high as 10.3% in scenario 2. Applying the Holm procedure to the z-test does not control the FWER,
and actually increases the error rate in some scenarios (such as 1 and 4). Applying the Bonferroni
correction to the z-test also does not control the FWER, as can be seen in the scenarios where all null
hypotheses are true. This may appear surprising at first, but the inflation occurs because the na¨ıve
z-test is not a valid level–α test for each elementary hypothesis. In contrast, both the adaptive closed
test and the Holm adaptive test strongly control the FWER.
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As for the power of the different methods, when at least one of the null hypotheses is true (as
in scenarios 2, 5, 6 and 7), the Holm z-test has substantially higher power than the closed z-test.
Indeed, the power more than doubles in all four scenarios, and even more than triples in scenario 5.
This dramatic increase in power demonstrates that in these scenarios, the closed z-test is not very
sensitive. This is because the test statistic for HI will be ‘diluted’ by the contribution from responses
belonging to the null hypotheses (Hi)i∈I that are true. It is only when all of the null hypotheses are
false, as in scenarios 3 and 8, that the power of the closed z-test is reasonable, with a slightly higher
power than the Holm z-test.
As for the adaptive tests, the adaptive closed test has a slightly lower power than the closed z-
test for all scenarios, with an absolute decrease of between 4.1% in scenario 5 and 7.5% in scenario
3. However, the Holm adaptive test has a substantially lower power than the Holm z-test, with the
latter having more than double the power. This demonstrates the high cost in terms of power that
controlling the FWER can incur for this randomization scheme. We return to this issue in Section 4.3.
Turning to the BAR scheme in Table 2, this time all of the methods strongly control the FWER.
All methods are slightly conservative, with the adaptive closed test being generally the closest to the
nominal 5% level. The Bonferroni-corrected z-test is noticeably more conservative than all the other
methods, particularly when there are three treatments. In terms of disjunctive power, if at least one
of the null hypotheses are true, we again see that the closed tests suffer from reduced power compared
to the Holm versions. However, with BAR the loss of power is less dramatic, with a maximum of a
33% relative decrease in power in scenario 5, but with much smaller decreases in scenarios 2 and 7 for
example. This time, the adaptive closed test has almost the same power as the closed z-test, losing a
maximum of only 1.4% in scenario 8. In addition, the Holm adaptive test and Holm z-test now have
comparable power, with a maximum loss of only 1.9% in scenarios 6 and 7. This indicates that for
BAR schemes, the adaptive tests do not lose out very much in terms of power.
4.2 Block randomization with a fixed control allocation
We now consider block randomized trials with a fixed control allocation, as presented in Section 3.1.
We use the setup of a trial with J = 3 blocks, with sizes (40, 40, 40) for the experimental treatments
and (20, 20, 20) for the control. In the burn-in period, five patients are allocated to each of the
treatments including the control. We set the true control mean µ = 0, and α = 0.05. We compare the
methods under the randomization schemes below.
Type I error inflator : The allocation probabilities for block j ∈ {1, . . . , J − 1}, patient k =
14
Dj + 1, . . . , Dj+1 and treatment l ∈ {2, . . . , h} are:
P (ak = 1) =

0 if
∑Dj
i=1 1{ai=1}
Xi
n1,j
> 0.5
1 otherwise
P (ak = l) =

1/(h− 1) if ∑Dji=1 1{ai=1} Xin1,j > 0.5
0 otherwise
where n1,j =
∑Dj
i=1 1{ai=1}.
BAR: The efficacy outcome for the ith treatment follows a N(µi, 1) distribution. For notational
convenience, let µ0 = µ; that is, the mean of the control. We assign independent normal priors to
the µi (i = 0, 1, . . . , h), such that µi ∼ N(µi,0, σ2i,0). At stage (j + 1), when the efficacy outcomes
x = (x1, . . . , xDj ) have been observed, the posterior for µi is as follows:
µi |X = x ∼ N
 σ2i,0
1 + ni,Kσ2i,0
Dj∑
k=1
1{ak=i}xk +
ni,K
1 + ni,Kσ2i,0
µi,0 ,
σ2i,0
1 + ni,Kσ2i,0

where ni,K =
∑DK
k=1 1{ak=i}.
We use a similar BAR scheme to the one in Wason and Trippa (2014). If there are h experimental
treatments, the randomization probabilities (pi1, . . . , pih) for the experimental treatments at the (j +
1)th stage are:
pii =
P (µi > µ0 |X = x)γ∑h
l=1 P (µl > µ0 |X = x)γ
In our simulations, for simplicity we set the priors µi,0 = 0 and σ
2
i,0 = 1, while γ = 0.5.
Simulation results: Table 1 gives the results for the type I error inflator randomization scheme,
while Table 2 gives the results for BAR. The auxiliary designs in all scenarios were simply random
draws from a discrete uniform distribution on {1, . . . , h}.
The results are broadly similar to those for the fully sequential setting presented in Section 4.1.
For the type I error inflator, we see that the closed z-test does not control the FWER in general
(as seen in scenarios 2, 6 and 7), and neither does applying the Holm procedure to the z-test. The
Bonferroni-corrected z-test has an inflated FWER when all null hypotheses are true, as in scenarios 1
and 4. In contrast, the adaptive tests strongly control the FWER in all scenarios. However, again this
comes at the cost of reduced power. There is a slight reduction in power between the closed z-test
and the closed adaptive test, of between 3 − 4% in absolute terms. In scenarios where at least one
null hypothesis is true, the Holm z-test has a much higher power than the Holm adaptive test, with
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the power more than doubling in these scenarios, and actually tripling in scenario 6.
As for the BAR scheme, all of the methods strongly control the FWER. This time, for some
scenarios the adaptive closed test basically achieves the nominal 5% level, as in scenarios 2 and 6.
When there are three treatments, the Bonferroni-corrected z-test can again be overly conservative,
as in scenarios 6 and 7. In contrast to the fully sequential setting, with block randomization we see
that the adaptive tests actually have the highest power out of all the methods in all scenarios except
scenario 2. When at least one null hypothesis is true, the Holm adaptive test has the highest power,
while when all null hypotheses are false the adaptive closed test has the highest power. The power
gains are small, but demonstrate that we do not always lose out in terms of power when using the
proposed adaptive tests.
Block randomization with an adaptive control allocation: In Appendix E.1, we present a simulation
study considering block randomization with an adaptive control allocation, as presented in Section 3.3.
The results are broadly similar to those presented above.
4.3 Summary
In summary, the simulation results show that in the randomization settings considered, our proposed
adaptive tests strongly control the FWER, as would be expected from theory. In contrast, the various
z-tests can all fail to control the error rate, as seen in the results for the type I error inflator. However,
given a more realistic randomization scheme, such as the BAR schemes we considered, the z-tests
achieve strong familywise error control. As for disjunctive power, we see that when at least one null
hypothesis is true, the closed tests suffer a very large drop in power compared to the Holm versions.
This is because of the ‘dilution’ of the test statistic as mentioned in Section 4.1. However, when all
the null hypotheses are true, then the closed test has the higher power, although the gains are at most
modest.
The adaptive tests can pay a large price in terms of power when compared with the z-tests, as
seen in the results for the type I error inflator. In Appendix E.2, we give an additional simulation
study with two treatments, where the randomization scheme used is simply a fixed allocation to
the experimental treatments but with unequal randomization probabilities. We show that when the
probability of assignment to treatment 2 is low (i.e. less than 0.2), there is a large drop in the power
of the adaptive tests for testing H1. This explains what is happening with the type I error inflator
when δ1 = 0, where in the majority of trial scenarios, apart from the unlikely event that treatment 1
stops early for ‘efficacy’, the probability of assignment to treatment 2 is zero by design. Hence, the
type I inflator is in fact close to a worst-case scenario for the adaptive tests.
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However, most adaptive randomization schemes are unlikely to have such extreme imbalances.
Indeed, authors such as Korn and Freidlin (2011) recommend restricting the probability of arm as-
signment to between 0.2 and 0.8 in order to prevent extreme patient allocation. Hence, for ‘sensible’
adaptive randomization schemes with such a restriction, we would not expect there to be a substantial
loss of power when using the Holm adaptive test compared with the Holm z-test, particularly in the
block randomized setting.
5 Case study
Finally, we illustrate our proposed methodology using an example based on a phase II placebo-
controlled trial in primary hypercholesterolemia (Roth et al., 2012). The purpose of the study was
to compare the effects of using the SAR236553 antibody with high-dose or lose-dose atorvastatin,
as compared with high-dose atorvastatin alone. The primary outcome was the least-squares mean
percent reduction from baseline of low-density lipoprotein cholesterol (LDL-C). Patients were ran-
domly assigned, in a 1:1:1 ratio, to receive 80 mg of atorvastatin plus placebo, 10 mg of atorvastatin
plus SAR236553, or 80 mg of atorvastatin plus SAR236553. For convenience, we label these different
interventions as the ‘control’, ‘low dose’ and ‘high dose’ respectively.
In the trial, the observed least-squares mean ± SE percent reduction from baseline in LDL-C was
17.3±3.5 for the control, 66.2±3.5 for the low dose and 72.3±3.5 for the high dose. There were N = 31
patients on the control, N = 31 patients on the low dose and N = 30 patients on the high dose, giving
a total of N = 61 patients on the two experimental doses. For our illustrative case study, we use the
observed values from the trial and assume that the distribution of the least-squares standardized mean
percent reduction from baseline of low-density LDL-C is N(17.3/3.5, 1) for the control, N(66.2/3.5, 1)
for the low dose, and N(72.3/3.5, 1) for the high dose.
Now suppose that the trial was carried out as an adaptive block randomized trial with a fixed
control allocation, as described in Section 3.1. Let the trial have J = 3 blocks, with block sizes (15,
15, 15) for the experimental treatments and (8, 8, 8) for the placebo. In the burn-in period, 7 patients
are allocated to the control and 8 patients are allocated to each of the experimental doses. Hence, a
total of 31 patients are on the control and 61 on the experimental treatments, as in the original trial.
We use the BAR scheme of Section 4.2, with priors µi,0 = 5 and σ
2
i,0 = 1 (i = 0, 1, 2), while γ = 0.5.
Table 5 shows the results for a simulated trial with the above parameters, where the BAR scheme
allocated 13 patients to the low dose and 32 patients to the high dose after the burn-in period. This
yields the natural weights used in the na¨ıve z-test of n′1 = 21 for the low dose and n′2 = 40 for the
high dose. The natural weight for the control is n0 = 31 by design. The auxiliary design randomly
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assigned 44 patients to the low or high dose in a 1:1 ratio, and allocated 21 patients to the low dose
and 23 patients to the high dose.
Table 5: Test statistics, p-values and weights for a simulated block randomized trial using a BAR
scheme.
Low dose High dose
z-test statistic 13.76 (p < 0.001) 15.50 (p < 0.001)
Adaptive test statistic 12.21 (p < 0.001) 16.22 (p < 0.001)
Natural weights n′1 = 21, n0 = 31 n′2 = 40, n0 = 31
Adaptive weights
w(1) = (30, 28.05, 21.49, 16.43) w(2) = (32, 34.09, 42.68, 46.08)
w(0) = (31, 31.73, 35.91, 42.76) w(0) = (31, 30.43, 28.86, 28.41)
The adaptive test statistic is slightly smaller than the z-test statistic for the low dose, while the
converse is true for the test statistics for the high dose. Looking at the adaptive weights for the burn-in
period and the three blocks, we see that for the low dose, the weights for the low dose decrease for
each block while the control weights increase. This pattern is reversed for the high dose. Given that
all the p-values are less than 0.001, using either the z-test or the adaptive test we would conclude
that adding the SAR236553 antibody to high-dose or low-dose atorvastatin leads to a statistically
significant reduction in LDL-C levels.
6 Discussion
A major regulatory concern over the use of response-adaptive trials in clinical practice has been en-
suring control of the type I error rate. We have proposed procedures that guarantee strong familywise
error control in the following multi-armed trial settings:
1. Fully sequential response-adaptive trials with a fixed control allocation (where the randomization
rule does not depend on the control information)
2. Block-randomized response-adaptive trials with a fixed control allocation
3. Block-randomized response-adaptive trials including an adaptive control allocation
These procedures are applicable to a large class of response-adaptive randomization rules, particu-
larly in settings (2) and (3) where there are no restrictions on the rule used. Hence both Bayesian and
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‘optimal’ response-adaptive randomization schemes proposed in the literature can be used without
adjustment, with only the final test statistic having to be modified.
In practice, to control the FWER we would recommend using the Holm adaptive test. Importantly,
it has a much higher power than the adaptive closed test when at least one of the null hypotheses are
true. As well, it only requires h hypothesis tests as compared with (2h − 1) hypothesis tests for the
adaptive closed test.
Our adaptive tests lead to unequal weightings of patients, which may be controversial (Burman
and Sonesson, 2006). One solution is to use the so-called ‘dual test’, and reject a hypothesis only if
both the adaptive test and the na¨ıve z-test rejects (Denne, 2001; Posch et al., 2003; Chen et al., 2004),
although this comes at the cost of reduced power.
We have assumed that the variances of the control and experimental treatments are known.
Fully accounting for unknown variances would add considerable complexity to our approach. In Ap-
pendix E.3, we show that estimating the common variance from the data does not inflate the FWER
when using the Holm adaptive test, for any of the simulation scenarios considered in this paper.
Our proposed procedures are designed for normally-distributed outcomes, and it would be useful
to apply our approach to binary outcomes as well. As a starting point, it may be possible to use the
asymptotically normal test statistic for contrasting each treatment arm with the control (Jennison
and Turnbull, 2000; Wason and Trippa, 2014), particularly in the block randomised setting.
Finally, although we did not explicitly consider it in this paper, the adaptive randomization proce-
dures used could also incorporate covariate information, so that the allocation probabilities vary across
patients with different covariates. These covariate-adjusted response-adaptive randomization schemes
are particularly useful when certain characteristics of the patients may be correlated with the primary
outcome (Hu and Rosenberger, 2006). A related setting would be biomaker-guided response-adaptive
trials, such as I-SPY 2.
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Appendix A: Derivation of the weights for familywise error control
in fully sequential response-adaptive trials
Below is a diagrammatic representation of the assignments and observations for the auxiliary design
compared to the actual design for the patients on the experimental treatments:
Actual design
a1 · · · ar ar+1 ar+2 · · · an
X1 · · · Xr Xr+1 Xr+2 · · · Xn
B
Auxiliary design
b1 · · · br br+1 br+2 · · · bn−1 bn
Y1 · · · Yr Yr+1 Yr+2 · · · Yn−1 Yn
B
where bk = ak, Yk = Xk (k = 1, . . . , r) and bn ∈ I by design.
Step 1
In step 1 we only consider the first response-adaptive allocation ar+1. We view the auxiliary and
actual trials as coming from a two-stage design, where the first stage for both is the burn-in period B,
as shown below.
Auxiliary design (step 1)
Stage 1︷ ︸︸ ︷
a1 · · · ar
Stage 2︷ ︸︸ ︷
br+1 br+2 · · · bn
X1 · · · Xr Yr+1 Yr+2 · · · Yn
B
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Actual design (step 1)
Stage 1︷ ︸︸ ︷
a1 · · · ar
Modified stage 2︷ ︸︸ ︷
ar+1 br+2 · · · bn
X1 · · · Xr Xr+1 Yr+2 · · · Yn
B
Given the interim data from B, we can determine the actual allocation ar+1. Indeed, ar+1 needs to
be known in order for the trial to continue. Hence the second stage for the actual design in step 1
is a data-dependent modification of the auxiliary design, where the allocation br+1 is set to ar+1. At
this step, all other allocations for the actual design remain the same as the auxiliary design. The
modification to the second stage in the actual design can only depend on data available at the end
of the interim stage; that is, the burn-in period. Hence when considering a fully sequential response-
adaptive scheme, we cannot adapt bk to ak for k > r + 1 at this step, and can only consider the
modification br+1 to ar+1.
Under the auxiliary two-stage design, the test statistic TI = T
(1)
I + T
(2)
I for the experimenal
treatments is decomposed into two parts, where T
(1)
I is calculated from the first stage data and T
(2)
I
is calculated from the second stage data. More explicitly,
T
(1)
I =
r∑
k=1
(
1{ak∈I}
Xk
n′I
)
T
(2)
I =
n∑
k=r+1
(
1{bk∈I}
Yk
n′I
)
−
n0∑
j=1
X0j
n0
.
Since the control data are independent of the design adaptations, we can consider these data as coming
from the second stage of the actual and auxiliary designs.
Using the conditional invariance principle, we seek a statistic T˜
(2)
I from the second stage data of
the actual design so that under HI and conditional on the interim data, the statistics T
(2)
I and T˜
(2)
I
have identical conditional distributions. Hence the modified statistic T˜I = T
(1)
I + T˜
(2)
I can be used as
the test statistic in the actual design, since T˜I has the same unconditional distribution under HI .
We now select weights w
(I)
r+1 and w
(0)
r+1 so that under HI , the statistic
T˜
(2)
I = 1{ar+1∈I}
Xr+1
w
(I)
r+1
+
n∑
k=r+2
(
1{bk∈I}
Yk
w
(I)
r+1
)
−
n0∑
j=1
X0j
w
(0)
r+1
has the same distribution as T
(2)
I conditional on the interim data D(1). Under HI , we have
T
(2)
I | D(1) ∼ N
(
µ
mI,r+1
n′I
− µ , mI,r+1
(n′I)2
+
1
n0
)
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T˜
(2)
I | D(1) ∼ N
µm˜I,r+1
w
(I)
r+1
− µ n0
w
(0)
r+1
,
m˜I,r+1(
w
(I)
r+1
)2 + n0(
w
(0)
r+1
)2

where m˜I,r+1 = mI,r+1 + 1{ar+1∈I,br+1 /∈I} − 1{ar+1 /∈I,br+1∈I}.
To match the conditional distributions we equate the conditional means and variances to give
w
(I)
r+1 =
λr+1m˜I,r+1 − [n0m˜I,r+1{ηr+1(n0 + m˜I,r+1)− λ2r+1}]1/2
λ2r+1 − n0ηr+1
w
(0)
r+1 =
n0w
(I)
r+1
m˜I,r+1 − λr+1w(I)r+1
where λr+1 = mI,r+1/n
′
I − 1 and ηr+1 = mI,r+1/(n′I)2 + 1/n0.
Hence the full modified statistic for the actual design in step 1 is
T˜I,r+1 = T˜I =
r+1∑
k=1
(
1{ak∈I}
Xk
w
(I)
k
)
+
n∑
k=r+2
(
1{bk∈I}
Yk
w
(I)
r+1
)
−
n0∑
j=1
X0j
w
(0)
r+1
where we define w
(I)
k = n
′
I (k = 1, . . . , r), and the (r + 1) subscript on T˜I,r+1 indicates that this is
the modified test statistic for the actual design after the first (r + 1) patients. By the conditional
invariance principle, T˜I,r+1 is a valid test statistic for the actual design.
Step 2
In step 2, we take the actual design from step 1 as the new auxiliary design. This means that the
modified test statistic T˜I,r+1, as defined above, is also taken forward from step 1 and is the valid
test statistic for the new auxiliary design. We again view the auxiliary and actual trials as two-stage
designs, where this time the first stage is the data from the first (r + 1) patients, as shown below.
Auxiliary design (step 2)
Stage 1︷ ︸︸ ︷
a1 · · · ar ar+1
Stage 2︷ ︸︸ ︷
br+2 br+3 · · · bn
X1 · · · Xr Xr+1 Yr+2 Yr+3 · · · Yn
B
Actual design (step 2)
Stage 1︷ ︸︸ ︷
a1 · · · ar ar+1
Modified stage 2︷ ︸︸ ︷
ar+2 br+3 · · · bn
X1 · · · Xr Xr+1 Xr+2 Yr+3 · · · Yn
B
Here the second stage for the new actual design is a modification of the new auxiliary design where
the allocation br+2 is set to ar+2.
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Under the auxiliary two-stage design, the test statistic T˜I,r+1 for the experimental treatments is
decomposed into the statistics calculated from the first and second stage data, T˜I,r+1 = T˜
(1)
I,r+1+T˜
(2)
I,r+1,
where now
T˜
(1)
I,r+1 =
r+1∑
k=1
(
1{ak∈I}
Xk
w
(I)
k
)
T˜
(2)
I,r+1 =
n∑
k=r+2
(
1{bk∈I}
Yk
w
(I)
r+1
)
−
n0∑
j=1
X0j
w
(0)
r+1
.
Following the conditional invariance principle like in step 1, we seek weights w
(I)
r+2 and w
(0)
r+2 so that
under HI , the statistic
T˜
(2)
I,r+2 = 1{ar+2∈I}
Xr+2
w
(I)
r+2
+
n∑
k=r+3
(
1{bk∈I}
Yk
w
(I)
r+2
)
−
n0∑
j=1
X0j
w
(0)
r+2
has the same distribution as T˜
(2)
I,r+1 conditional on the interim data D(1). Matching the conditional
distributions by equating the conditional means and variances gives
w
(I)
r+2 =
λr+2m˜I,r+2 − [n0m˜I,r+2{ηr+2(n0 + m˜I,r+2)− λ2r+2}]1/2
λ2r+2 − n0ηr+2
w
(0)
r+2 =
n0w
(I)
r+2
m˜I,r+2 − λr+2w(I)r+2
where
λr+2 =
mI,r+2
w
(I)
1
− n0
w
(0)
1
, ηr+2 =
mI,r+2(
w
(I)
1
)2 + n0(
w
(0)
1
)2
m˜I,r+2 = mI,r+2 + 1{ar+2∈I,br+2 /∈I} − 1{ar+2 /∈I,br+2∈I}.
Hence the full modified statistic for the actual design in step 2 is
T˜I,r+2 =
r+2∑
k=1
(
1{ak∈I}
Xk
w
(I)
k
)
+
n∑
k=r+3
(
1{bk∈I}
Yk
w
(I)
r+2
)
−
n0∑
j=1
X0j
w
(0)
r+2
This statistic is taken forward to the next step of the process as the valid test statistic for the new
auxiliary design.
Inductive step
We now repeat the process above, at each step taking forward the actual design as the new auxiliary
design. The actual design at step l of the process (l = 2, . . . , n − r − 1) is a modification of the
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new auxiliary design where br+l is set to ar+l. The valid test statistic for the new auxiliary design is
T˜I,r+l−1, taken forward from the previous step of the process, where we provide an explicit expression
for the test statistics shortly. The diagrammatic representation of step l of the process is given below.
Auxiliary design (step l)
Stage 1︷ ︸︸ ︷
a1 · · · ar ar+1 ar+2 · · · ar+l−1
Stage 2︷ ︸︸ ︷
br+l br+l+1 · · · bn
X1 · · · Xr Xr+1 Xr+2 · · · Xr+l−1 Yr+l Yr+l+1 · · · Yn
B
Actual design (step l)
Stage 1︷ ︸︸ ︷
a1 · · · ar ar+1 ar+2 · · · ar+l−1
Modified stage 2︷ ︸︸ ︷
ar+l br+l+1 · · · bn
X1 · · · Xr Xr+1 Xr+2 · · · Xr+l−1 Xr+l Yr+l+1 · · · Yn
B
Using these auxiliary and actual designs, we select new weights w
(I)
r+l and w
(0)
r+l so that under HI
the conditional distributions of the second stage statistics are the same. This yields the new test
statistic T˜I,r+l for the actual design in step l. For notational convenience, we introduce the following
functions:
f(λ, η,m) =
λm− {mn0(n0η − λ2)}1/2
λ− n0η
g(λ,w,m) =
n0w
m− λw
Given the weights w
(I)
r+l−1 and w
(0)
r+l−1 found in the previous step, let
λr+l =
mI,r+l
w
(I)
r+l−1
− n0
w
(0)
r+l−1
, ηr+l =
mI,r+l(
w
(I)
r+l−1
)2 + n0(
w
(0)
r+l−1
)2
m˜I,r+l = mI,r+l + 1{ar+l∈I,br+l /∈I} − 1{ar+l /∈I,br+l∈I}.
The weights w
(I)
r+l and w
(0)
r+l are given by
w
(I)
r+l = f(λr+l, ηr+l, m˜I,r+l)
w
(0)
r+l = g(λr+l, w
(I)
r+l, m˜I,r+l)
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The corresponding test statistics T˜I,r+k for k = 1, . . . , l are:
T˜I,r+k =
r+k∑
j=1
(
1{aj∈I}
Xj
w
(I)
j
)
+
n∑
j=r+k+1
(
1{bj∈I}
Yj
w
(I)
r+k
)
−
n0∑
j=1
X0j
w
(0)
r+k
Final step
In the final step of the process, the second stage data for the auxiliary and actual designs is a single
allocation:
Auxiliary design (final step)
a1 · · · ar ar+1 ar+2 · · · an−1 bn
X1 · · · Xr Xr+1 Xr+2 · · · Xn−1 Yn
B
Actual design (final step)
a1 · · · ar ar+1 ar+2 · · · an−1 an
X1 · · · Xr Xr+1 Xr+2 · · · Xn−1 Xn
B
Under the auxiliary design, the test statistic T˜I,n−1 is decomposed into the following first and
second stage statistics, since bn ∈ I by design:
T˜
(1)
I,n−1 =
n−1∑
k=1
(
1{ak∈I}
Xk
w
(I)
k
)
, T˜
(2)
I,n−1 =
Yn
w
(I)
n−1
−
n0∑
j=1
X0j
w
(0)
n−1
where w
(0)
n−1 and w
(I)
k have been defined in the previous steps for k = r + 1, . . . , n − 1. As before, we
want to select a weight w
(I)
n so that
T˜
(2)
I,n = 1{an∈I}
Xn
w
(I)
n
−
n0∑
j=1
X0j
w
(0)
n
has the same conditional distribution as T
(2)
I,n−1 under HI . If an ∈ I then the auxiliary and actual
designs are identical, and so w
(I)
n = w
(I)
n−1 and w
(0)
n = w
(0)
n−1.
However, if an /∈ I, then we do not have enough degrees of freedom with a single weight w(0)n to
match both the conditional means and variances. Hence, we split the n0 control observations into two
groups of size m0,1 and m0,2, where m0,1 ≥ 1, m0,2 ≥ 1 and m0,1 + m0,2 = n0. In practice, to keep
the weights as close to the natural weight n0 for as many of the control observations as possible, we
recommend setting m0,1 = n0 − 1 and m0,2 = 1, which is what we use for the simulation studies in
Section 4.2 of the paper.
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We select weights w
(0)
n,1 and w
(0)
n,2 so that under HI , the statistic
T˜
(2)
I,n = −
m0,1∑
j=1
X0j
w
(0)
n,1
−
n0∑
j=m0,1+1
X0j
w
(0)
n,2
has the same distribution as T
(2)
I,n conditional on the interim data D(1). Under HI , we have
T
(2)
I,n |D(1) ∼ N
µ 1
w
(I)
n−1
− µ n0
w
(0)
n−1
,
1(
w
(I)
n−1
)2 + n0(
w
(0)
n−1
)2

T˜
(2)
I,n |D(1) ∼ N
−µm0,1
w
(0)
n,1
− µm0,2
w
(0)
n,2
,
m0,1(
w
(0)
1,n
)2 + m0,2(
w
(0)
n,2
)2

Equating the conditional means and variances gives
w
(0)
n,1 =
−2m0,1λn − [m0,1m0,2{ηn(m0,1 +m0,2)− λ2n}]1/2
λ2n −m0,2ηn
w
(0)
n,2 = −
m0,2w
(0)
n,1
m0,1 + λnw
(0)
n,1
where λn = 1/w
(I)
n−1 − n0/w(0)n−1 and ηn = 1/(w(I)n−1)2 + n0/(w(0)n−1)2.
For notational convenience, define the following functions
F1(w,m1,m2) =

w if an ∈ I
−2m1λn −
√
m1m2(ηn(m1 +m2)− λ2n)
λ2n −m2ηn
if an /∈ I
F2(w,m1,m2) =

w if an ∈ I
− m2F1(w,m1,m2)
m1 + λnF1(w,m1,m2)
if an /∈ I
We can express the weights w
(0)
n,1 and w
(0)
n,2 for the controls, for either an ∈ I or an /∈ I, as w(0)n,1 =
F1(w
(0)
n−1,m0,1,m0,2) and w
(0)
n,2 = F2(w
(0)
n−1,m0,1,m0,2).
The final test statistic for testing hypothesis HI is as follows:
T˜I =
n∑
k=1
(
1{ak∈I}
Xk
w
(I)
k
)
−
n0∑
j=1
X0j
w
(0)
n,j
where
w
(I)
k = n
′
I , w
(0)
k = n0 (k = 1, . . . , r)
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w
(I)
r+l = f(λr+l, ηr+l, m˜I,r+l) (l = 1, . . . , n− r)
w
(0)
r+l = g(λr+l, w
(I)
r+l, m˜I,r+l) (l = 1, . . . , n− r)
w
(0)
n,j = F1(w
(0)
n−1,m0,1,m0,2) (j = 1, . . . ,m0,1)
w
(0)
n,j = F2(w
(0)
n−1,m0,1,m0,2) (j = m0,1 + 1, . . . , n0)
We reject HI if T˜I is greater than zα (1/n
′
I + 1/n0)
1/2.
Appendix B: Numerical example for fully sequential response-adaptive
trials
As a simple illustration of how the weights change over the course of a trial, consider testing h = 2
experimental treatments. We set α = 0.05, n0 = 10, n = 11 and r1 = r2 = 1. Suppose we have no a
priori reason to favour one treatment over the other, and so we simply choose the auxiliary design to
be an equal randomization of the two treatments:
b = 1 2 2 1 2 2 1 1 2 1 ∗
Here the vertical line indicates where the burn-in period ends, and the * represents the allocation
for bn, which by design must satisfy bn ∈ I. We set m0,1 = 9 and m0,2 = 1, so that w(0)1 = · · · = w(0)9 .
Below are the weights w(I), w
(0)
1 and w
(0)
10 for a variety of actual allocations.
Table 6: An actual allocation a that is almost the same as the auxiliary design b. The weights that
would be used in the na¨ıve z-test are n0 = 10, n1 = 4 and n2 = 7.
a = 1 2 2 2 1 2 2 1 2 1 2
b = 1 2 2 1 2 2 1 1 2 1 *
w(1) = 6 6 6 5.16 6 6 4.94 4.94 4.94 4.94 - w
(0)
1 = 9.74, w
(0)
10 = −5.38
w(2) = 6 6 6 7.01 5.74 5.74 7.63 7.63 7.63 7.63 7.63 w
(0)
1 = w
(0)
10 = 9.58
Table 7: An actual allocation a that is the opposite of the auxiliary design b. The weights that would
be used in the na¨ıve z-test are n0 = 10, n1 = 6 and n2 = 5.
a = 1 2 1 2 1 1 2 2 1 2 1
b = 1 2 2 1 2 2 1 1 2 1 *
w(1) = 6 6 6.81 5.83 6.81 8 6.51 4.94 6.51 4.09 4.09 w
(0)
1 = w
(0)
10 = 10.17
w(2) = 6 6 5.16 6 4.94 3.81 4.94 6.51 4.10 6.51 - w
(0)
1 = 9.23, w
(0)
10 = −7.59
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Table 8: An extreme actual allocation a that is equal to 1 after the burn-in period. The weights that
would be used in the na¨ıve z-test are n0 = 10, n1 = 10 and n2 = 2.
a = 1 2 1 1 1 1 1 1 1 1 1
b = 1 2 2 1 2 2 1 1 2 1 *
w(1) = 6 6 6.81 6.81 8.00 9.45 9.45 9.45 12.95 12.95 12.95 w
(0)
1 = w
(0)
10 = 8.82
w(2) = 6 6 5.16 5.16 4.28 3.33 3.33 3.33 2.23 2.23 - w
(0)
1 = 14.73, w
(0)
10 = −2.25
Table 9: An extreme actual allocation a that is equal to 2 after the burn-in period. The weights that
would be used in the na¨ıve z-test are n0 = 10, n1 = 1 and n2 = 10.
a = 1 2 2 2 2 2 2 2 2 2 2
b = 1 2 2 1 2 2 1 1 2 1 *
w(1) = 6 6 6 5.16 5.16 5.16 4.28 3.33 3.33 2.23 - w
(0)
1 = 14.73, w
(0)
10 = −2.25
w(2) = 6 6 6 7.01 7.01 7.01 9.44 12.91 12.91 22.89 22.89 w
(0)
1 = w
(0)
10 = 9.01
Appendix C: Derivation of the weights for familywise error control
in block randomized response-adaptive trials with a fixed control al-
location
Below is a diagrammatic representation of the assignments and observations for the auxiliary design
compared to the actual design (for the patients on the experimental treatments):
Actual design
aB a1 a2 · · · aJ
XB X1 X2 · · · XJ
Auxiliary design bB b1 b2 · · · bJ
YB Y1 Y2 · · · YJ
Here aB = (a1, . . . , ar) and XB = (X1, . . . , Xr) refer to the burn-in period B, while
aj = (aDj−1+1, . . . , aDj ) and Xj = (XDj−1+1, . . . , XDj ) represent the response-adaptive allocations and
observations in block j (j = 1, . . . , J). By design, bB = aB, YB = XB, while bj = (bDj−1+1, . . . , bDj ) and
Yj = (YDj−1+1, . . . , YDj ) represent the auxiliary allocations and observations in block j (j = 1, . . . , J).
As before, we require bn ∈ I.
Step 1
In step 1 we only consider the response-adaptive allocations for the first block a1. We view the auxil-
iary and actual trials as coming from a two-stage design, where the first stage for both is the burn-in
period B, as shown below.
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Auxiliary design (step 1)
aB
Stage 2︷ ︸︸ ︷
b1 b2 · · · bJ
XB X1 X2 · · · XJ
Actual design (step 1)
aB
Modified stage 2︷ ︸︸ ︷
a1 b2 · · · bJ
XB X1 Y2 · · · YJ
Given the interim data from B, we can determine the actual allocations a1 for the first block. Hence
the second stage for the actual design in step 1 is a data-dependent modification of the auxiliary
design, where the allocations b1 are set to a1. All the other allocations for the actual design remain
the same as the auxiliary design.
Under the auxiliary two-stage design, the test statistic TI is decomposed into two parts, with
TI = T
(1)
I + T
(2)
I , where T
(1)
I is calculated from the first stage data and T
(2)
I is calculated from the
second stage data. More explicitly,
T
(1)
I =
r∑
k=1
(
1{ak∈I}
Yk
n′I
)
−
r0∑
k=1
X0k
n0
T
(2)
I =
n∑
k=r+1
(
1{bk∈I}
Yk
n′I
)
−
n0∑
k=r0+1
X0k
n0
Following the conditional invariance principle, we select weights w
(I)
1 and w
(0)
1 so that under HI ,
the statistic
T˜
(2)
I =
D1∑
k=r+1
1{ak∈I}
Xk
w
(I)
1
+
n∑
k=D1+1
1{bk∈I}
Yk
w
(I)
1
−
n0∑
k=r0+1
X0k
w
(0)
1
has the same distribution as T
(2)
I conditional on the interim data D(1). Under HI , we have
T
(2)
I |D(1) ∼ N
(
µ
mI,1
n′I
− µm0,1
n′0
,
mI,1
(n′I)2
+
m0,1
(n′0)2
)
T˜
(2)
I |D(1) ∼ N
µm˜I,1
w
(I)
1
− µm0,1
w
(0)
1
,
m˜I,1(
w
(I)
1
)2 + m0,1(
w
(0)
1
)2

where m˜I,1 = mI,2 +
∑D1
k=r+1 1{ak∈I}.
To match the conditional distributions we equate the conditional means and variances to give
w
(I)
1 =
λ1m˜I,1 − [m˜I,1m0,1{η1(m0,1 + m˜I,1)− λ21}]1/2
λ21 −m0,1η1
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w
(0)
1 =
m0,1w
(I)
1
m˜I,1 − λ1w(I)1
where λ1 = mI,1/n
′
I −m0,1/n0 and η1 = mI,1/(n′I)2 +m0,1/(n0)2.
Hence the full modified statistic for the actual design in step 1 is
T˜I,1 = T˜I =
1∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
+
n∑
k=D1+1
1{bk∈I}
Yk
w
(I)
1
−
r0∑
k=1
X0k
w
(0)
0
−
n0∑
k=r0+1
X0k
w
(0)
1
where w
(0)
0 = n0 and w
(I)
0 = n
′
I . This statistic is taken forward to the next step of the process as the
valid test statistic for the new auxiliary design.
Inductive step
We continue the process above, at each step taking forward the actual design as the new auxiliary
design. The actual design at step l of the process (l ∈ {1, . . . , J − 1}) is a modification of the new
auxiliary design where the allocations bl are set to al. The valid test statistic for the new auxiliary
design is T˜I,l, taken forward from the previous step of the process. The diagrammatic representation
of step l of the process is given below:
Auxiliary design (step l)
Stage 1︷ ︸︸ ︷
aB a1 · · · al−1
Stage 2︷ ︸︸ ︷
bl bl+1 · · · bJ
XB X1 · · · Xl−1 Yl Yl+1 · · · YJ
Actual design (step l)
Stage 1︷ ︸︸ ︷
aB a1 · · · al−1
Modified stage 2︷ ︸︸ ︷
al bl+1 · · · bJ
XB X1 · · · Xl−1 Xl Yl+1 · · · YJ
Using these auxiliary and actual designs, we select new weights w
(I)
l and w
(0)
l so that under HI
the conditional distributions of the second stage statistics are the same. This yields the new test
statistic T˜I,l for the actual design in step l. For notational convenience, we introduce the following
functions:
f(λ, η,mI ,m0) =
λmI − [mIm0{η(m0 +mI)− λ2}]1/2
λ−m0η
g(λ,w,mI ,m0) =
m0w
mI − λw
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Given the weights w
(I)
l−1 and w
(0)
l−1 found in the previous step, let
λl =
mI,l
w
(I)
l−1
− m0,l
w
(0)
l−1
, ηl =
mI,l(
w
(I)
l−1
)2 + m0,l(
w
(0)
l−1
)2
m˜I,l = mI,l+1 +
Dl∑
k=Dl−1+1
1{ak∈I}
The weights w
(I)
l and w
(0)
l are given by
w
(I)
l = f(λl, ηl, m˜I,l,m0,l)
w
(0)
l = g(λl, w
(I)
l , m˜I,l,m0,l)
The corresponding test statistic T˜I,l is:
T˜I,l =
l∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
+
n∑
k=Dl+1
1{bk∈I}
Yk
w
(I)
l
−
l∑
j=0
D0,j∑
k=D0,j−1+1
X0k
w
(0)
j
−
n0∑
k=D0,l+1
X0k
w
(0)
l
where we define D0,−1 = 0.
Final step
In the final step of the process, the second stage data for the auxiliary and actual designs is the final
block:
Auxiliary design (final step)
Stage 1︷ ︸︸ ︷
aB a1 · · · aJ−1 bJ
XB X1 · · · XJ−1 YJ
Actual design (step 2)
Stage 1︷ ︸︸ ︷
aB a1 · · · aJ−1 aJ
XB X1 · · · XJ−1 XJ
Under the auxiliary design, the test statistic T˜I,J−1 is decomposed into the following first and
second stage statistics, where bn ∈ I by design:
T˜
(1)
I,J−1 =
J−1∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
−
J−1∑
j=0
D0,j∑
k=D0,j−1+1
X0k
w
(0)
j
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T˜
(2)
I,J−1 =
n∑
k=DJ−1+1
1{bk∈I}
Yk
w
(0)
J−1
−
n0∑
k=D0,J−1+1
X0k
w
(0)
J−1
where w
(0)
j and w
(I)
j have been defined in the previous steps for j = 1, . . . , J − 1. We want to select
weights w
(I)
J and w
(0)
J so that
T˜
(2)
I,J =
n∑
k=DJ−1+1
1{ak∈I}
Xk
w
(I)
J
−
n0∑
k=D0,J−1+1
X0k
w
(0)
J
has the same conditional distribution as T
(2)
I,J−1 under HI . Let
λJ =
mI,J
w
(I)
J−1
− m0,J
w
(0)
J−1
, ηJ =
mI,J(
w
(I)
J−1
)2 + m0,J(
w
(0)
J−1
)2
If mI,J > 0, then let m˜I,J =
∑n
k=DJ−1+1 1{ak∈I}. As before, the weights w
(I)
J and w
(0)
J are given
by
w
(I)
J = f(λJ , ηJ , m˜I,J ,m0,J)
w
(0)
J = g(λl, w
(I)
J , m˜I,J ,m0,J)
In this case, the final test statistic for testing hypothesis HI is as follows:
T˜I =
J∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
−
J∑
j=0
D0,j∑
k=D0,j−1+1
X0k
w
(0)
j
where
w
(I)
0 = n
′
I , w
(0)
0 = n0
w
(I)
j = f(λj , ηj , m˜I,j ,m0,j) (j = 1, . . . , J)
w
(0)
j = g(λj , w
(I)
j , m˜I,j ,m0,j) (j = 1, . . . , J)
We reject HI if T˜I is greater than zα(1/n
′
I + 1/n
′
0)
1/2.
However, if mI,J = 0 then we do not have enough degrees of freedom with a single weight w
(0)
J to
match both the conditional means and variances. In this case, since by design m0,J = d0J > 1, we
consider separately the first n0,J,1 control observations and the next n0,J,2 control observations, where
n0,J,1 > 0, n0,J,2 > 0 and n0,J,1 + n0,J,2 = d0J . In order to keep the weights as close to the natural
weight n0 for as many of the control observations as possible, we recommend setting n0,J,1 = d0J − 1
and n0,J,2 = 1, which is what we use for the simulation studies in Section 4.3 of the paper.
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Letting D0,J,1 = D0,J−1 + n0,J,1, we select weights w
(0)
J,1 and w
(0)
J,2 so that under HI , the statistic
T˜
(2)
I,J = −
D0,J,1∑
k=D0,J−1+1
X0k
w
(0)
J,1
−
n0∑
k=D0,J,1+1
X0k
w
(0)
J,2
has the same distribution as T
(2)
I,J−1 conditional on the interim data D(1). Under HI , we have
T˜
(2)
I,J |D(1) ∼ N
−µn0,J,1
w
(0)
J,1
− µn0,J,2
w
(0)
J,2
,
n0,J,1(
w
(0)
J,1
)2 + n0,J,2(
w
(0)
J,2
)2

Equating the conditional means and variances gives
w
(I)
J,1 =
−n0,J,1λJ − [n0,J,1n0,J,2{ηJ(n0,J,1 + n0,J,2)− λ2J}]1/2
λ2J − n0,J,2ηJ
w
(I)
J,2 = −
n0,J,2w
(I)
J,1
n0,J,1 + λJw
(I)
J,1
In this case, the final test statistic for testing hypothesis HI is as follows:
T˜I =
J−1∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
−
J−1∑
j=0
D0,j∑
k=D0,j−1+1
X0k
w
(0)
j
−
D0,J,1∑
k=D0,J−1+1
X0k
w
(0)
J,1
−
n0∑
k=D0,J,1+1
X0k
w
(0)
J,2
We reject HI if T˜I is greater than zα(1/n
′
I + 1/n0)
1/2.
Appendix D: Derivation of the weights for familywise error control in
block randomized response-adaptive trials with an adaptive control
allocation
Let ak = 0 if the kth patient is allocated to the control and n0 =
∑n
k=1 1{ak=0} denote the total
number of allocations to the control. The na¨ıve z-test for HI rejects HI if the test statistic
TI =
n∑
k=1
(
1{ak∈I}
Xk
nI
)
−
n∑
k=1
(
1{ak=0}
Xk
n0
)
is greater than zα (1/nI + 1/n0)
1/2.
The trial starts with a a burn-in period B, which allocates r0 > 0 patients to the control and ri > 0
patients to the ith treatment (i = 1, . . . , h), where r0 and the ri are again fixed in advance. Hence a
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total of r =
∑h
i=0 ri patients are allocated to the experimental treatments during the burn-in period.
The auxiliary design for hypothesis HI starts with a burn-in period B with r patients that is
identical to the actual design. The subsequent n − r − 2 allocations are given by a fixed sequence
(br+1, . . . , bn−2). The allocation bn−1 is to the control, while the allocation bn must be in I. For
the auxiliary design, let n′0 and n′i denote the total number of allocations to the control and the ith
treatment respectively (i = 1, . . . , h), including the burn-in period.
Step 1
In step 1 we only consider the response-adaptive allocations for the first block a1. We view the auxil-
iary and actual trials as coming from a two-stage design, where the first stage for both is the burn-in
period B, as shown below.
Auxiliary design (step 1)
aB
Stage 2︷ ︸︸ ︷
a1 a2 · · · aJ
XB X1 X2 · · · XJ
Actual design (step 1)
aB
Modified stage 2︷ ︸︸ ︷
a1 b2 · · · bJ
XB X1 Y2 · · · YJ
Under the auxiliary two-stage design, the test statistic TI = T
(1)
I +T
(2)
I for the experimenal treatments
is decomposed into two parts, where T
(1)
I is calculated from the first stage data and T
(2)
I is calculated
from the second stage data. More explicitly,
T
(1)
I =
r∑
k=1
(
1{ak∈I}
Yk
n′I
)
−
r∑
k=1
(
1{ak=0}
Yk
n′0
)
T
(2)
I =
n∑
k=r+1
(
1{bk∈I}
Yk
n′I
)
−
n∑
k=r+1
(
1{bk=0}
Yk
n′0
)
We now select weights w
(I)
1 and w
(0)
1 so that under HI , the statistic
T˜
(2)
I =
D1∑
k=r+1
1{ak∈I}
Xk
w
(I)
1
+
n∑
k=D1+1
1{bk∈I}
Yk
w
(I)
1
−
D1∑
k=r+1
1{ak=0}
Xk
w
(0)
1
−
n∑
k=D1+1
1{bk=0}
Yk
w
(0)
1
has the same distribution as T
(2)
I conditional on the interim data D(1). Under HI , we have
T
(2)
I |D(1) ∼ N
(
µ
mI,1
n′I
− µm0,1
n′0
,
mI,1
(n′I)2
+
m0,1
(n′0)2
)
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T˜
(2)
I |D(1) ∼ N
µm˜I,1
w
(I)
1
− µm˜0,1
w
(0)
1
,
m˜I,1(
w
(I)
1
)2 + m˜0,1(
w
(0)
1
)2

where
m˜I,1 = mI,2 +
D1∑
k=r+1
1{ak∈I}, m˜0,1 = m0,2 +
D1∑
k=r+1
1{ak=0}.
To match the conditional distributions we equate the conditional means and variances to give
w
(I)
1 =
λ1m˜I,1 − [m˜I,1m˜0,1{η1(m˜0,1 + m˜I,1)− λ21}]1/2
λ21 − m˜0,1η1
w
(0)
1 =
m˜0,1w
(I)
1
m˜I,1 − λ1w(I)1
where λ1 = mI,1/n
′
I −m0,1/n′0 and η1 = mI,1/(n′I)2 +m0,1/(n′0)2.
Hence the full modified statistic for the actual design in step 1 is
T˜I,1 = T˜I =
1∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
+
n∑
k=D1+1
1{bk∈I}
Yk
w
(I)
1
−
1∑
j=0
Dj∑
k=Dj−1+1
1{ak=0}
Xk
w
(0)
j
−
n∑
k=D1+1
1{bk=0}
Yk
w
(0)
1
where we define D−1 = 0, w
(I)
0 = n
′
I and w
(0)
0 = n
′
0. By the conditional invariance principle, T˜I,1 is a
valid test statistic for the actual design.
Inductive step
We now repeat the process above, at each step taking forward the actual design as the new auxiliary
design. The actual design at step l of the process (l ∈ {1, . . . , J − 1}) is a modification of the new
auxiliary design where the allocations bl are set to al. The valid test statistic for the new auxiliary
design is T˜I,l, taken forward from the previous step of the process. The diagrammatic representation
of step l of the process is given below.
Auxiliary design (step l)
Stage 1︷ ︸︸ ︷
aB a1 · · · al−1
Stage 2︷ ︸︸ ︷
bl bl+1 · · · bJ
XB X1 · · · Xl−1 Yl Yl+1 · · · YJ
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Actual design (step l)
Stage 1︷ ︸︸ ︷
aB a1 · · · al−1
Modified stage 2︷ ︸︸ ︷
al bl+1 · · · bJ
XB X1 · · · Xl−1 Xl Yl+1 · · · YJ
Using these auxiliary and actual designs, we select new weights w
(I)
l and w
(0)
l so that under HI the
conditional distributions of the second stage statistic are the same. This yields the new test statistic
T˜I,l for the actual design in step l.
For notational convenience, we introduce the following functions:
f(λ, η,mI ,m0) =
λmI − [mIm0{η(m0 +mI)− λ2}]1/2
λ−m0η
g(λ,w,mI ,m0) =
m0w
mI − λw
Given the weights w
(I)
l−1 and w
(0)
l−1 found in the previous step, let
λl =
mI,l
w
(I)
l−1
− m0,l
w
(0)
l−1
, ηl =
mI,l(
w
(I)
l−1
)2 + m0,l(
w
(0)
l−1
)2
m˜I,l = mI,l+1 +
Dl∑
k=Dl−1+1
1{ak∈I}
m˜0,l = m0,l+1 +
Dl∑
k=Dl−1+1
1{ak=0}
The weights w
(I)
l and w
(0)
l are given by
w
(I)
l = f(λl, ηl, m˜I,l, m˜0,l)
w
(0)
l = g(λl, w
(I)
l , m˜I,l, m˜0,l)
The corresponding test statistic T˜I,l is:
T˜I,l =
l∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
+
n∑
k=Dl+1
1{bk∈I}
Yk
w
(I)
l
−
l∑
j=0
Dj∑
k=Dj−1+1
1{ak=0}
Xk
w
(0)
j
−
n∑
k=Dl+1
1{bk=0}
Yk
w
(0)
l
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Final step
Under the auxiliary design, the test statistic T˜I,J−1 is decomposed into the following first and second
stage statistics, where bn−1 = 0 and bn ∈ I by design:
T˜
(1)
I,J−1 =
J−1∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
−
J−1∑
j=0
Dj∑
k=Dj−1+1
1{ak=0}
Xk
w
(0)
j
T˜
(2)
I,J−1 =
n∑
k=DJ−1+1
1{bk∈I}
Yk
w
(0)
J−1
−
n∑
k=DJ−1+1
1{bk=0}
Yk
w
(0)
J−1
where w
(0)
j and w
(I)
j have been defined in the previous steps for j = 1, . . . , J − 1. We want to select
weights w
(I)
J and w
(0)
J so that
T˜
(2)
I,J =
n∑
k=DJ−1+1
1{ak∈I}
Xk
w
(I)
J
−
n∑
k=DJ−1+1
1{ak=0}
Xk
w
(0)
J
has the same conditional distribution as T
(2)
I,J−1 under HI . For notational convenience, let
λJ =
mI,J
w
(I)
J−1
− m0,J
w
(0)
J−1
, ηJ =
mI,J(
w
(I)
J−1
)2 + m0,J(
w
(0)
J−1
)2
If mI,J > 0 and m0,J > 0, then let
m˜I,J =
n∑
k=DJ−1+1
1{ak∈I} , m˜0,J =
n∑
k=DJ−1+1
1{ak=0}.
The weights w
(I)
J and w
(0)
J are given by
w
(I)
J = f(λJ , ηJ , m˜I,J , m˜0,J)
w
(0)
J = g(λl, w
(I)
J , m˜I,J , m˜0,J)
In this case, the final test statistic for testing hypothesis HI is as follows:
T˜I =
J∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
−
J∑
j=0
Dj∑
k=Dj−1+1
1{ak=0}
Xk
w
(0)
j
where
w
(I)
0 = n
′
I , w
(0)
0 = n
′
0
w
(I)
j = f(λj , ηj , m˜I,j , m˜0,j) (j = 1, . . . , J)
w
(0)
j = g(λj , w
(I)
j , m˜I,j , m˜0,j) (j = 1, . . . , J)
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We reject HI if T˜I is greater than zα (1/n
′
I + 1/n
′
0)
1/2.
However, if mI,J = 0 and m0,J > 1, then we do not have enough degrees of freedom with a single
weight w
(0)
J to match both the conditional means and variances. In this case, we consider separately
the first n0,J,1 control observations and the next n0,J,2 control observations, where n0,J,1 > 0, n0,J,2 > 0
and n0,J,1 + n0,J,2 = m0,J . As before, we recommend setting n0,J,1 = m0,J − 1 and n0,J,2 = 1, which is
what we use for the simulation studies in Section E.1.
Suppose the (D0,J,1)th patient receives the (n0,J,1)th allocation to the control in block J . We select
weights w
(0)
J,1 and w
(0)
J,2 so that under HI , the statistic
T˜
(2)
I,J = −
D0,J,1∑
k=DJ−1+1
1{ak=0}
Xk
w
(0)
J,1
−
n∑
k=D0,J,1+1
1{ak=0}
Xk
w
(0)
J,2
has the same distribution as T
(2)
I,J−1 conditional on the interim data D(1). Under HI , we have
T˜
(2)
I,J |D(1) ∼ N
−µn0,J,1
w
(0)
J,1
− µn0,J,2
w
(0)
J,2
,
n0,J,1(
w
(0)
J,1
)2 + n0,J,2(
w
(0)
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Equating the conditional means and variances gives
w
(I)
J,1 =
−n0,J,1λJ − [n0,J,1n0,J,2{ηJ(n0,J,1 + n0,J,2)− λ2J}]1/2
λ2J − n0,J,2ηJ
w
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In this case, the final test statistic for testing hypothesis HI is as follows:
T˜I =
J−1∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
−
J−1∑
j=0
Dj∑
k=Dj−1+1
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Xk
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(0)
j
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D0,J,1∑
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Xk
w
(0)
J,2
We reject HI if T˜I is greater than zα (1/n
′
I + 1/n
′
0)
1/2.
If m0,J = 0 and mI,J > 1, then we do not have enough degrees of freedom with a single weight
w
(I)
J to match both the conditional means and variances. In this case, we consider separately the
first nI,J,1 and the next nI,J,2 observations from treatments in I, where nI,J,1 > 0, nI,J,2 > 0 and
nI,J,1 + nI,J,2 = mI,J . We recommend setting nI,J,1 = mI,J − 1 and nI,J,2 = 1, which is used for the
simulation studies in Section E.1.
Suppose the (DI,J,1)th patient receives the (nI,J,1)th allocation to a treatment in I in block J . We
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select weights w
(I)
J,1 and w
(I)
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J,2
has the same distribution as T
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Equating the conditional means and variances gives
w
(I)
J,1 =
nI,J,1λJ − [nI,J,1nI,J,2{ηJ(nI,J,1 + nI,J,2)− λ2J}]1/2
λ2J − nI,J,2ηJ
w
(I)
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nI,J,2w
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In this case, the final test statistic for testing hypothesis HI is as follows:
T˜I =
J−1∑
j=0
Dj∑
k=Dj−1+1
1{ak∈I}
Xk
w
(I)
j
−
J−1∑
j=0
Dj∑
k=Dj−1+1
1{ak=0}
Xk
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(0)
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+
DI,J,1∑
k=DJ−1+1
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Xk
w
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+
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w
(I)
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We reject HI if T˜I is greater than zα (1/n
′
I + 1/n
′
0)
1/2.
Finally, if max(m0,J ,mI,J) ≤ 1 and min(m0,J ,mI,J) = 0 then we cannot match the conditional
means and variances and hence out adaptive procedure fails to give a valid test statistic. However,
such a scenario is unlikely given reasonably large block sizes and a minimum allocation probability to
the control, for example. In our simulation study in Section E.1, this scenario was never observed.
The weights for the final block may not be real-valued and hence the procedure can fail to give a
valid test statistic. It can also happen that the weights for the experimental treatment are negative. In
this case, our procedure no longer necessarily controls the FWER for the composite null hypothesesHi :
δi ≤ 0, but only the point null hypotheses Hi : δi = 0. Hence the adaptive test that allows for response-
adaptive allocation to the control does so at the cost of being less robust and flexible. Appendix E.1
gives some simulation results to illustrate these issues.
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Appendix E: Additional simulation results
E.1 Block randomization with an adaptive allocation to the control
We consider block randomization with an adaptive control allocation, as presented in Section 3.4 in
the paper. We use the setup of a trial with J = 3 blocks and sizes (50, 50, 50). In the burn-in period,
5 patients are allocated to each of the treatments including the control. We again set the true control
mean µ = 0, and α = 0.05.
Type I error inflator : The allocation probabilities for block j ∈ {1, . . . , J − 1}, patient k =
Dj + 1, . . . , Dj+1 and treatment l ∈ {0, 2, . . . , h} are:
P (ak = 1) =

0 if
∑Dj
i=1 1{ai=1}
Xi
n1,j
> 0.5
1 otherwise
P (ak = l) =

1/h if
∑Dj
i=1 1{ai=1}
Xi
n1,j
> 0.5
0 otherwise
where n1,j =
∑Dj
i=1 1{ai=1}.
Bayesian adaptive randomization: The priors and posteriors are the same as in Section 4.3 in the
paper, and we use a similar Bayesian adaptive randomization scheme. If there are h experimental
treatments, then the randomization probabilities (pi0, pi1, . . . , pih) at the (j + 1)th stage are:
pii ∝

P (µi>µ0|X1=x1,...,XDj=xDj )γ∑h
l=1 P (µl>µ0|X1=x1,...,XDj=xDj )γ
(i = 1, . . . , h)
1
h exp (max(mˆ1j , mˆ2j , . . . , mˆhj)− mˆ0j)ν (i = 0)
where mˆij is the current arm-specific sample size for the ith treatment at the end of the jth stage. In
our simulations, for simplicity we set the priors µi,0 = 0 and σ
2
i,0 = 1, while γ = 0.5 and ν = 0.1.
Simulation results: Table 10 gives the results for the type I error inflator randomization scheme,
while Table 11 gives the result for BAR. For each scenario, we ran 105 simulated trials. The auxiliary
designs in all scenarios were random draws from a discrete uniform distribution on {0, 1, . . . , h}.
The results here are again broadly similar to those for the fully sequential setting, and the block
randomization setting with a fixed allocation to the control. For the type I error inflator, the various
z-tests do not strongly control the FWER. The adaptive tests do achieve strong error control, but this
comes at the cost of a very large decrease in power when compared with the Holm z-test.
For the BAR scheme, again all methods strongly control the FWER. This time, the z-tests have
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Table 10: Familywise error rate and disjunctive power for the type I error inflator, for block random-
ization with an adaptive control allocation. There were 105 simulated trials for each set of parameter
values.
Adaptive closed test Adaptive test (Holm) Closed z-test z-test (Holm) z-test (Bonferroni)
Parameter values Error Power Error Power Error Power Error Power Error Power
1. δ1 = δ2 = 0 3.8 - 4.9 - 4.4 - 6.7 - 6.7 -
2. δ1 = 0, δ2 = 1 4.8 19.1 3.7 25.1 8.2 25.4 7.8 67.2 4.3 67.1
3. δ1 = δ2 = 0.5 - 90.1 - 84.4 - 93.3 - 89.9 - 89.9
4. δ1 = δ2 = δ3 = 0 3.2 - 4.1 - 3.9 - 6.2 - 6.2 -
5. δ1 = δ2 = 0, δ3 = 1 3.8 14.0 4.4 21.9 4.8 20.0 6.5 61.7 4.8 61.6
6. δ1 = 0, δ2 = δ3 = 1 4.8 19.1 3.4 24.6 8.4 26.4 7.5 80.6 3.2 80.6
7. δ1 = 0, δ2 = 0.5, δ3 = 1 4.5 17.0 3.0 22.6 8.0 23.7 6.6 66.9 2.9 66.8
8. δ1 = δ2 = δ3 = 0.5 - 87.5 - 78.4 - 91.8 - 86.9 - 86.9
Table 11: Familywise error rate and disjunctive power for BAR, for block randomization with an
adaptive control allocation. There were 105 simulated trials for each set of parameter values.
Adaptive closed test Adaptive test (Holm) Closed z-test z-test (Holm) z-test (Bonferroni)
Parameter values Error Power Error Power Error Power Error Power Error Power
1. δ1 = δ2 = 0 4.6 - 4.5 - 4.6 - 4.4 - 4.4 -
2. δ1 = 0, δ2 = 0.5 5.0 54.4 4.9 76.4 4.8 56.1 4.7 78.0 2.4 78.0
3. δ1 = δ2 = 0.5 - 90.6 - 87.4 - 91.5 - 88.3 - 88.3
4. δ1 = δ2 = δ3 = 0 4.0 - 4.3 - 3.9 - 4.2 - 4.2 -
5. δ1 = δ2 = 0, δ3 = 0.5 4.6 29.0 4.5 61.4 4.6 29.9 4.4 62.9 3.1 62.9
6. δ1 = 0, δ2 = δ3 = 0.5 4.9 56.4 4.5 76.1 4.7 57.4 4.4 77.3 1.6 77.3
7. δ1 = 0, δ2 = 0.25, δ3 = 0.5 4.5 41.7 3.6 62.9 4.3 42.7 3.5 63.7 1.7 63.7
8. δ1 = δ2 = δ3 = 0.5 - 85.9 - 82.0 - 86.9 - 83.0 - 83.0
the highest power. When at least one null hypothesis is true the Holm z-test has the highest power,
although there is only a small gain compared to the Holm adaptive test. When all null hypotheses
are false, the closed z-test has a slightly higher power than the closed adaptive test.
With an adaptive control allocation, the weights of the adaptive test can become imaginary, or
negative for the experimental treatments. In the former case, we set the modified test statistics
T˜I = −∞ and do not reject the null hypothesis HI , which will preserve the FWER at the cost of
lower power. In the latter case, we cannot use the adaptive test for the composite null hypotheses
Hi : δi ≤ 0, although it will still be a valid test for the point null hypotheses Hi : δi = 0.
We also considered how often at least one imaginary or negative weight occurs over the 105 simu-
lations for the two randomization schemes. Tables 12 and 13 give the percentage of simulations where
the weights for the experimental treatments are imaginary or negative, for the type I error inflator
and BAR scheme respectively.
For the type I error inflator, there are essentially no negative weights for either adaptive test. The
Holm adaptive tests has imaginary weights less than than 0.6% of the time in all scenarios. In contrast,
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Table 12: Percentage of simulations where at least one imaginary or negative weight occurs for the
type I error inflator, with 105 simulated trials for each set of parameter values.
Adaptive closed test Adaptive test (Holm)
Parameter values Imaginary Negative Imaginary Negative
1. δ1 = δ2 = 0 0.09 0.00 0.09 0.00
2. δ1 = 0, δ2 = 1 0.09 0.00 0.09 0.00
3. δ1 = δ2 = 0.5 0.07 0.00 0.07 0.00
4. δ1 = δ2 = δ3 = 0 6.81 0.00 0.18 0.00
5. δ1 = δ2 = 0, δ3 = 1 6.86 0.00 0.17 0.00
6. δ1 = 0, δ2 = δ3 = 1 6.84 0.00 0.17 0.00
7. δ1 = 0, δ2 = 0.5, δ3 = 1 6.89 0.00 0.17 0.00
8. δ1 = δ2 = δ3 = 0.5 2.67 0.00 0.53 0.00
Table 13: Percentage of simulations where at least one imaginary or negative weight occurs for BAR,
with 105 simulated trials for each set of parameter values.
Adaptive closed test Adaptive test (Holm)
Parameter values Imaginary Negative Imaginary Negative
1. δ1 = δ2 = 0 0.10 0.09 0.10 0.09
2. δ1 = 0, δ2 = 1 0.14 0.10 0.14 0.10
3. δ1 = δ2 = 0.5 0.00 0.08 0.00 0.08
4. δ1 = δ2 = δ3 = 0 0.29 0.12 0.29 0.12
5. δ1 = δ2 = 0, δ3 = 1 0.35 0.07 0.34 0.07
6. δ1 = 0, δ2 = δ3 = 1 0.25 0.08 0.25 0.08
7. δ1 = 0, δ2 = 0.5, δ3 = 1 0.20 0.11 0.19 0.11
8. δ1 = δ2 = δ3 = 0.5 0.01 0.08 0.01 0.08
when there are three treatments, the adaptive closed tests can have up to 7% of the simulations having
imaginary weights. This shows that for more extreme randomization schemes, the adaptive closed test
is not very robust, and is much less robust than the Holm adaptive test. For BAR, the percentage of
imaginary weights is less than 0.4% for either adaptive test. This time there are negative weights in
some simulations, but the percentage is very low, at less than 0.2%.
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E.2 Power of the adaptive test
The adaptive tests can pay a large price in terms of power when compared with the z-tests, as seen
in the results for the type I error inflator. In order to understand what is happening in this setting,
we conducted an additional simulation study. Suppose we are testing h = 2 treatments, and that
the randomization scheme used is simply a fixed allocation to the experimental treatments, but with
unequal randomization probabilities. Let p2 denote the probability of assignment to treatment 2.
Firstly consider the fully sequential trial setup of Section 4.2 in the paper, with δ1 = 0, δ2 = 0.7.
Figure 1 shows how the power of the Holm adaptive test and z-test compares as p2 varies. We see that
when p2 > 0.5, the adaptive test only suffers a small loss of power compared to the z-test. However,
when p2 < 0.5, the adaptive test loses an increasing amount of power.
Now consider the block randomization setup of Section 4.3 in the paper, with δ1 = 0, δ2 = 0.5.
Figure 2 shows that this time, the power of the adaptive test is very close, or even equal, to the z-test
when p2 > 1/3. This shows how the adaptive test is more robust in terms of power in the block
randomization setting compared to the fully sequential version.
Figure 3 shows how the powers differ for δ1 = 0, δ2 = 1 and p2 < 0.2. We can see that when
p2 < 0.15, there is a noticeable and increasing divergence between the powers of the two tests. Indeed,
when p2 = 0 the power of the Holm z-test is three times that of the Holm adaptive test. This shows
what is happening with the type I error inflator when δ1 = 0, where in the majority of trial scenarios,
apart from the unlikely event that treatment 1 stops early for ‘efficacy’, p2 = 0 by design. Hence, the
type I inflator is in fact close to a worst-case scenario for the adaptive tests.
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Figure 1: Power of the Holm adaptive test and Holm z-test as a function of the probability of
assignment to treatment 2. We use the fully sequential trial setup of Section 4.2 in the paper, with
h = 2 treatments and δ1 = 0, δ2 = 0.7.
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Figure 2: Power of the Holm adaptive test and Holm z-test as a function of the probability of
assignment to treatment 2. We use the block randomized trial setup of Section 4.3 in the paper, with
h = 2 treatments and δ1 = 0, δ2 = 0.5.
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Figure 3: Power of the Holm adaptive test and Holm z-test as a function of the probability of
assignment to treatment 2. We use the block randomized trial setup of Section 4.3 in the paper, with
h = 2 treatments and δ1 = 0, δ2 = 1.
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E.3 Using the pooled sample variance
In this section, we assume that σ2 is unknown and will be estimated at the end of the trial using
the pooled sample variance σˆ2 (as defined below) of the experimental treatments and control. More
precisely, given the adaptive test statistic T˜I , to test hypothesis HI we compare T˜I/σˆ with the critical
value zα(1/n
′
I+1/n
′
0). We rerun all the simulation studies in Section 4 of the paper and Appendix E.1,
with exactly the same setup except for this change in the test procedure. Due to the extra variability
induced by estimating the pooled sample variance, we simulate 106 trials for each set of parameter
values.
Given that there are h experimental treatments, the formula for the pooled sample variance is
σˆ2 =
∑h
i=0 (ni − 1)s2i∑h
i=0 (ni − 1)
(1)
where s2i is the sample variance for treatment i (i = 0, 1, . . . , h).
For an adaptive control allocation,
s2i =
1
ni − 1
n∑
k=1
(
1{ak=i}
(
Xk − X¯i
)2)
for i = 0, 1, . . . , h
where
X¯i =
1
ni
ni∑
k=1
1{ak=i}Xk for i = 0, 1, . . . , h
For a fixed control allocation, the formulae for s2i and X¯i are the same for i = 1, . . . , h, but now
s20 =
1
n0 − 1
n0∑
j=1
(
X0j − X¯0
)2
X¯0 =
1
n0
n0∑
j=1
X0j
52
E.3.1 Fully sequential randomization (with a fixed control allocation)
Table 14 gives the results for the type I error inflator, and Table 15 the results for BAR. Compared to
assuming a known variance of σ2 = 1, for all sets of parameter values both the FWER and disjunctive
power increase slightly. For the type I error inflator, the Bonferroni-corrected z-test now has a FWER
above 5% in scenarios 2 and 5, while the adaptive closed test now has a FWER of 5.1% in scenario 6.
However, the Holm adaptive test still achieves strong FWER control. For BAR, as before all the
testing strategies control the FWER.
Table 14: Familywise error rate and disjunctive power for the type I error inflator in the fully
sequential setting. There were 106 simulated trials for each set of parameter values.
Adaptive closed test Adaptive test (Holm) Closed z-test z-test (Holm) z-test (Bonferroni)
Parameter values Error Power Error Power Error Power Error Power Error Power
1. δ1 = δ2 = 0 3.4 - 4.9 - 4.9 - 7.5 - 7.5 -
2. δ1 = 0, δ2 = 1 5.0 21.8 3.8 27.6 10.5 26.8 10.1 63.9 5.3 63.8
3. δ1 = δ2 = 0.5 - 62.4 - 52.7 - 69.9 - 61.6 - 61.6
4. δ1 = δ2 = δ3 = 0 3.0 - 4.3 - 4.3 - 6.4 - 6.4
5. δ1 = δ2 = 0, δ3 = 1 3.6 13.2 4.6 24.9 5.4 17.3 7.0 54.6 5.1 54.5
6. δ1 = 0, δ2 = δ3 = 1 5.1 22.6 3.6 28.8 10.3 27.5 9.6 72.8 3.6 72.8
7. δ1 = 0, δ2 = 0.5, δ3 = 1 4.5 19.5 3.0 25.5 9.6 24.4 7.9 59.0 3.7 58.9
8. δ1 = δ2 = δ3 = 0.5 - 51.6 - 43.0 - 57.8 - 50.0 - 50.0
Table 15: Familywise error rate and disjunctive power for BAR in the fully sequential setting. There
were 106 simulated trials for each set of parameter values.
Adaptive closed test Adaptive test (Holm) Closed z-test z-test (Holm) z-test (Bonferroni)
Parameter values Error Power Error Power Error Power Error Power Error Power
1. δ1 = δ2 = 0 4.8 - 4.7 - 4.9 - 4.2 - 4.2 -
2. δ1 = 0, δ2 = 0.5 4.7 46.7 4.4 52.6 4.0 46.9 3.7 53.6 2.0 53.5
3. δ1 = δ2 = 0.5 - 70.9 - 66.7 - 71.1 - 65.8 - 65.8
4. δ1 = δ2 = δ3 = 0 4.2 - 4.6 - 4.3 - 4.2 - 4.2
5. δ1 = δ2 = 0, δ3 = 1 4.7 59.9 4.8 88.8 4.6 60.1 4.2 90.2 2.9 90.2
6. δ1 = 0, δ2 = δ3 = 1 5.0 89.9 5.0 95.3 4.2 89.9 4.2 95.8 1.4 95.8
7. δ1 = 0, δ2 = 0.5, δ3 = 1 4.7 75.1 4.2 88.6 4.1 75.6 3.6 89.7 1.5 89.7
8. δ1 = δ2 = δ3 = 0.5 - 57.2 - 53.2 - 58.0 - 52.8 - 52.8
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E.3.2 Block randomization with a fixed control allocation
Table 16 gives the results for the type I error inflator, and Table 17 the results for BAR. Compared to
assuming a known variance of σ2 = 1, for all sets of parameter values both the FWER and disjunctive
power increase slightly. For the type I error inflator, the same scenarios as before lead to an inflation
of the FWER. In particular, both the adaptive closed test and the Holm adaptive test achieve FWER
control. For BAR, as before all the testing strategies control the FWER.
Table 16: Familywise error rate and disjunctive power for the type I error inflator, for block ran-
domization with a fixed control allocation. There were 106 simulated trials for each set of parameter
values.
Adaptive closed test Adaptive test (Holm) Closed z-test z-test (Holm) z-test (Bonferroni)
Parameter values Error Power Error Power Error Power Error Power Error Power
1. δ1 = δ2 = 0 3.9 - 4.9 - 4.7 - 6.9 - 6.9 -
2. δ1 = 0, δ2 = 1 4.9 22.0 3.7 27.0 8.4 25.6 7.9 61.1 4.4 61.0
3. δ1 = δ2 = 0.5 - 92.6 - 87.7 - 94.6 - 91.6 - 91.6
4. δ1 = δ2 = δ3 = 0 3.2 - 4.1 - 4.1 - 6.3 - 6.3
5. δ1 = δ2 = 0, δ3 = 1 3.8 14.2 4.4 23.4 4.8 18.3 6.4 61.4 4.7 61.2
6. δ1 = 0, δ2 = δ3 = 1 5.0 20.1 3.3 26.1 8.3 23.1 7.5 79.8 3.0 79.8
7. δ1 = 0, δ2 = 0.5, δ3 = 1 4.8 17.7 3.0 23.9 8.1 21.3 6.8 66.3 3.0 66.3
8. δ1 = δ2 = δ3 = 0.5 - 91.2 - 83.1 - 93.9 - 89.5 - 89.5
Table 17: Familywise error rate and disjunctive power for BAR, for block randomization with a fixed
control allocation. There were 106 simulated trials for each set of parameter values. There were 106
simulated trials for each set of parameter values.
Adaptive closed test Adaptive test (Holm) Closed z-test z-test (Holm) z-test (Bonferroni)
Parameter values Error Power Error Power Error Power Error Power Error Power
1. δ1 = δ2 = 0 4.7 - 4.6 - 4.7 - 4.5 - 4.5 -
2. δ1 = 0, δ2 = 0.5 5.0 61.3 5.0 82.6 4.9 61.3 4.9 82.9 2.5 82.8
3. δ1 = δ2 = 0.5 - 94.5 - 92.2 - 94.5 - 92.2 - 92.2
4. δ1 = δ2 = δ3 = 0 3.9 - 4.6 - 3.8 - 4.4 - 4.4
5. δ1 = δ2 = 0, δ3 = 0.5 4.5 36.0 4.6 71.7 4.5 36.0 4.4 71.7 3.1 71.7
6. δ1 = 0, δ2 = δ3 = 0.5 5.0 67.3 4.7 85.4 4.8 66.8 4.5 85.2 1.6 85.2
7. δ1 = 0, δ2 = 0.25, δ3 = 0.5 4.6 51.1 3.8 72.9 4.4 50.9 3.6 72.6 1.6 72.6
8. δ1 = δ2 = δ3 = 0.5 - 93.3 - 90.4 - 93.2 - 90.2 - 90.2
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E.3.3 Block randomisation with an adaptive control allocation
Table 18 gives the results for the type I error inflator, and Table 19 the results for BAR. Compared to
assuming a known variance of σ2 = 1, for all sets of parameter values both the FWER and disjunctive
power increase slightly. For the type I error inflator, the same scenarios as before lead to an inflation
of the FWER. In particular, both the adaptive closed test and the Holm adaptive test achieve FWER
control. However, for BAR, the adaptive closed test now has a FWER of 5.1% in scenario 2 (the
FWER is controlled for all other scenarios and testing procedures).
Table 18: Familywise error rate and disjunctive power for the type I error inflator, for block random-
ization with an adaptive control allocation. There were 106 simulated trials for each set of parameter
values.
Adaptive closed test Adaptive test (Holm) Closed z-test z-test (Holm) z-test (Bonferroni)
Parameter values Error Power Error Power Error Power Error Power Error Power
1. δ1 = δ2 = 0 3.9 - 5.0 - 4.6 - 7.0 - 7.0 -
2. δ1 = 0, δ2 = 1 5.0 19.1 3.8 25.1 8.4 25.7 7.9 67.4 4.5 67.3
3. δ1 = δ2 = 0.5 - 90.0 - 84.4 - 93.2 - 89.8 - 89.8
4. δ1 = δ2 = δ3 = 0 3.3 - 4.1 - 4.0 - 6.6 - 6.6 -
5. δ1 = δ2 = 0, δ3 = 1 3.8 14.0 4.5 22.1 4.9 20.0 6.6 62.0 4.9 61.9
6. δ1 = 0, δ2 = δ3 = 1 5.0 19.2 3.5 24.7 8.5 26.5 7.7 80.6 3.2 80.6
7. δ1 = 0, δ2 = 0.5, δ3 = 1 4.7 17.1 3.1 22.6 8.2 24.0 6.8 67.1 3.2 67.0
8. δ1 = δ2 = δ3 = 0.5 - 87.4 - 78.3 - 91.7 - 86.8 - 86.8
Table 19: Familywise error rate and disjunctive power for BAR, for block randomization with an
adaptive control allocation. There were 106 simulated trials for each set of parameter values.
Adaptive closed test Adaptive test (Holm) Closed z-test z-test (Holm) z-test (Bonferroni)
Parameter values Error Power Error Power Error Power Error Power Error Power
1. δ1 = δ2 = 0 4.7 - 4.7 - 4.7 - 4.6 - 4.6 -
2. δ1 = 0, δ2 = 0.5 5.1 54.6 5.0 76.5 5.0 56.2 4.9 78.1 2.5 78.1
3. δ1 = δ2 = 0.5 - 90.5 - 87.3 - 91.4 - 88.3 - 88.3
4. δ1 = δ2 = δ3 = 0 4.0 - 4.5 - 4.0 - 4.4 - 4.4 -
5. δ1 = δ2 = 0, δ3 = 0.5 4.7 29.2 4.6 61.3 4.6 30.1 4.4 62.8 3.1 62.8
6. δ1 = 0, δ2 = δ3 = 0.5 5.0 56.5 4.7 75.9 4.9 57.5 4.5 77.1 1.7 77.1
7. δ1 = 0, δ2 = 0.25, δ3 = 0.5 4.5 41.8 3.7 62.4 4.4 42.8 3.5 63.7 1.7 63.6
8. δ1 = δ2 = δ3 = 0.5 - 85.9 - 81.9 - 86.9 - 82.9 - 82.9
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